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I Abbreviations 
 
AD  Alzheimer’s disease 
Arg-1  arginase type 1  
ATP  adenosine triphosphate 
Aβ amyloid β 
BBB blood brain barrier 
bFGF  basic fibroblast growth factor 
BSA  bovine serum albumin 
CD  cluster of differentiation molecule  
CNS  central nervous system 
COX-2  cyclooxygenase-2 
CXCL10  chemokine (C-X-C motif) ligand 10 
DAPI  4',6-diamidino-2-phenylindole 
DMSO  dimethyl sulfoxide 
EB  embryoid body 
ESC  embryonic stem cell 
ESdM  embryonic stem cell derived 
 microglial precursors 
FBS  fetal bovine serum  
FGF  fibroblast growth factor  
GAPDH  glyceraldehyde-3-phosphate 
 dehydrogenase 
GM-CSF  granulocyte-macrophage colony 
 stimulating factor 
h   hours 
Iba1   ionized calcium binding adaptor 
 molecule 1 
ICAM  intercellular adhesion molecule  
ICM inner cell mass 
IFN  interferon 
IL  interleukin 
iNOS  inducible nitric oxide synthase  
LIF  leukemia inhibitory factor 
LPS  lipopolysaccharide 
MEF  mouse embryonic fibroblast 
MHC  major histocompatibility complex  
min  minutes 
MS  multiple sclerosis   
nGS  normal goat serum 
NO  nitric oxide 
NOS2  nitric oxide synthase-2 
PAMP  pathogen-associated molecular 
 pattern 
PBS  phosphate-buffered saline 
PD  Parkinson’s disease 
PFA  paraformaldehyde 
PLL  poly-L-lysine  
PNS peripheral nervous system 
PRR  pattern recognition receptor  
qRT-PCR  quantitative real-time polymerase 
 chain reaction 
rm  recombinant mouse  
RT reverse transcription  
s seconds 
ScavR1  scavenger receptor type 1  
SHP-1  Src homology phosphatase-1 
TGF-β  transforming growth factor-β 
Th  t-helper cell type 
TLR  toll-like receptor 
TNF  tumor necrosis factor 
TREM2 triggering receptor expressed on 
 myeloid cells 2  
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II Abstract 
Microglia are the resident immune cells of the central nervous system (CNS). Microglia undergo 
rapid activation in response to even minor pathological changes in the CNS. The activation state of 
microglia and tissue macrophages is characterized by two extremes that are known as M1 and 
M2. M1 is triggered upon pro-inflammatory stimuli and lead to the secretion of molecules 
involved in brain defense but also in neurotoxicity. M2 arises upon anti-inflammatory stimuli and 
is hallmarked by the secretion of molecules that mediate tolerance and neuroprotection. The aim 
of this study was to investigate the in vitro polarization capacity of microglia into M1 and M2 
subtypes. Primary microglia are hard to obtain in sufficient number and therefore a recently 
developed protocol was applied to differentiate microglial precursors from mouse embryonic 
stem (ES) cells. The obtained ES cell derived microglial precursors (ESdM) were shown to be an 
appropriate substitute to primary microglia. Here we showed that ESdM stimulated with 
interferon-γ (IFN-γ) and lipopolysaccharide (LPS) display typical M1 characteristics like higher 
transcription levels of pro-inflammatory cytokines as well as an increase in the expression level of 
M1 surface markers. They also secreted significantly higher levels of the chemokine CXCL10 and 
nitric oxide than untreated or interleukin-4 (IL-4) treated cells. These results indicate that ESdM 
can be polarized into a cytotoxic subtype in vitro using IFN-γ and LPS. However, no evidence 
indicating that ESdM were polarized into a neuroprotective M2 subtype by IL-4 treatment has 
been found. Even though an increase in the transcription level of anti-inflammatory cytokines was 
observed upon IL-4 treatment, this increase was not significant. In addition, no increase in the 
expression levels of M2 markers or in the secretion of the anti-inflammatory cytokine IL-10 were 
found upon IL-4 treatment indicating that IL-4 might be insufficient to polarize ESdM into M2 
subtype in vitro. Further experiments are required to better understand the mechanisms of 
microglial sub-differentiation and to determine the stability of the acquired M1 and M2 
phenotypes over time. 
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1. INTRODUCTION 
1.1.  Microglia 
The central nervous system (CNS), composed of the brain and the spinal cord, contains two main 
cell types: about 100 billion neurons and 10-50 times more supporting cells called glia (Banati, 
2003). Neurons are excitable cells that transmit impulses within the CNS and the peripheral 
nervous system (PNS), which allows the initiation of appropriate responses by the effector tissues 
in the periphery. Glial cells can be distinguished from neurons through the absence of an axon 
(Rajadhyaksha and Khan, 2002). They play an essential role in correct neuronal development and 
in mature neuron functions (Baumann and Pham-Dinh, 2001). Indeed, they maintain homeostasis, 
form myelin and provide support and protection for neurons. They are therefore known as the 
“supporting cells” of the nervous system. In the adult brain, the four main functions of glial cells 
are to surround neurons and hold them in place, to supply nutrients and oxygen to neurons, to 
insulate one neuron from another and to destroy pathogens and remove dead neurons (Miller et 
al., 2009). Moreover, they modulate neurotransmission (Auld and Robitaille, 2003). The two 
major classes of glial cells present in the vertebrate CNS are macroglia, composed mainly of 
astrocytes and oligodendrocytes, and microglia. It is well accepted that astrocytes and microglia 
react to CNS damage, and are therefore the two major types of reactive glial cells (Streit et al., 
1999; Takuma et al., 2004). 
Astrocytes, which are the most prevalent type of glial cells in the CNS (Takuma et al., 2004) have a 
distinct star-shaped appearance (see Fig. 1.1 A) and perform a large and diverse variety of 
functions that are essential for the brain. For example, they provide structural, metabolic and 
trophic support to neurons, control the homeostasis of the neuronal extracellular environment, 
modulate neuronal synaptic activity and participate in the glial-vascular interface of the blood 
brain barrier (BBB); (Hatton, 2002; Takuma et al., 2004; Abbott et al., 2006).  
Oligodendrocytes (see Fig. 1.1 B) are the myelin-forming cells exclusively in the CNS, as Schwann 
cells perform this role in the PNS. Processes of the oligodendrocytes contact axons and envelop a 
stretch of them. Along a single axon, adjacent segments of the myelin sheath belong to distinctive 
oligodendrocytes. The advantages conferred by these myelin sheaths are the rapid conduction of 
nerve impulses, fidelity of transfer signaling on long distances and space economy (Baumann and 
Pham-Dinh, 2001). There are some diseases in which the myelin is affected and therefore the 
communication between neurons disturbed. This leads to paralysis or motor dysfunction and 
prove the importance of oligodendrocytes and myelination in the CNS. 
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Microglia (see Fig. 1.1 C) are the resident immune cells of the CNS and constitute approximately 
10-20 % of the total glial cell population. In the CNS they ensure the first line of innate immune 
response (Raivich et al., 1999; Banati, 2003; Fetler and Amigorena, 2005; Napoli and Neumann, 
2009). They were first examined by Pio del Rio-Hortega, who gave them their name in the 1920s. 
During the 1980s, new staining methods made it possible to visualize them reliably and this 
almost forgotten glial cell type regained interest. Microglia play important roles throughout life in 
supporting and maintaining neuronal function, health, homeostasis and survival. Indeed, they 
phagocytose potentially deleterious debris and secrete neurotrophic factors to promote tissue 
repair (Streit, 2000; Luo et al., 2010). One of the characteristic features of microglia is that they 
are quite sensitive to disturbance of the extracellular homeostasis and become rapidly activated 
in response to even minor pathological changes in the CNS (Kreutzberg, 1996; Streit, 2000). 
Microglia participate in the initiation of brain inflammation and neuronal death by the production 
and release of many detrimental factors like pro-inflammatory cytokines, reactive oxygen species 
and nitric oxide (NO); (Colton, 2009; Henkel et al., 2009). However, it is now well accepted that 
microglial cells are also able to orchestrate repair and reconstruction in the CNS via the 
production of anti-inflammatory cytokines and neurotrophic factors (Henkel et al., 2009).  
 
 
  
 
 
 
 
 
 
A B C 
Fig. 1.1: Morphology of the three main glial cells in the brain.  
(A) Fluorescent picture of an astrocyte (Picture from P. Magistretti, Institute of Physiology, UNIL, Lausanne). 
(B) Fluorescent picture of an oligodendrocyte in culture (Picture from Prof. Elek Molnar Lab, Department of 
Anatomy, University of Bristol). (C) Fluorescent picture of a mouse microglia stained against Iba1 (Picture from 
L. Bodea, Neural Regeneration Group, Institute of Reconstructive Neurobiology, University of Bonn). 
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1.1.1. Origin of microglia 
Santiago Ramón y Cajal was the first in 1913 who observed a “third element” apart of neurons 
and neuroglia in the CNS. After that, Pio del Rio-Hortega developed the silver carbonate staining 
and by using it, was able to identify two different types of cells within this “third element”, the 
oligodendrocytes and the microglia. These two cell types not only differ by their external 
morphology but also by their embryonic origin. Indeed, Pio del Rio-Hortega claimed that 
oligodendrocytes had an ectodermal origin but that microglia were of mesodermal origin (Kaur et 
al., 2001). Despite intense study, the precise origin and cell lineage of microglia is still under 
debate, which is mainly due to the lack of cell type-specific markers (Dalmau et al., 2003; Chan et 
al., 2007). Even if there are actually two main hypotheses concerning their origin, several 
statements were proposed during the last half-century. The first main hypothesis is that microglial 
precursors are of neuroectodermal origin like neurons and the remaining glial cells (Fedoroff et 
al., 1997). The second hypothesis states that microglia are derived from mesodermal progenitors 
and therefore originate from outside the developing nervous tissue. This means that during 
development these cells have to migrate through extravascular routes, differentiate into microglia 
and colonize the nervous system (Cuadros and Navascues, 1998; Kaur et al., 2001; Chan et al., 
2007).  
It was shown that microglia populate the CNS during neuroectodermal development in mice in 
two waves. First, during embryonic development (E9.5 – E10.5), ionized calcium binding adaptor 
molecule 1 (Iba1)-positive cells suddenly appear in the brain when the blood circulation has not 
yet been established (Chan et al., 2007). From E13.5 until around birth, Iba1-positive cells 
increase in number in the brain and spinal cord (Chan et al., 2007).  
During the last decade, it was proposed that two different types of microglia are present in the 
brain: microglia produced during development and the ones that are responsible for microglial 
turnover in the adult brain and under pathological conditions (Cuadros and Navascues, 1998). The 
first type of microglia populates the nervous system primarily during embryonic and fetal 
development (Cuadros and Navascues, 1998). The second type are microglia derived from bone-
marrow that are able to migrate into the adult CNS under certain specific pathological conditions 
(Ladeby et al., 2005; Simard et al., 2006; Mildner et al., 2007). However, it was shown that 
microgliosis in the adult brain is mainly due to the proliferation of CNS resident microglia 
(Ransohoff, 2007).  
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1.1.2. Microglial morphologies and their functional roles 
Microglial cells are extremely plastic cells and undergo a variety of structural changes depending 
on their location and environment. Three distinct forms with different functions can be observed 
in the CNS depending on the brain state; amoeboid, resting/ramified and reactive/activated 
microglia. 
Amoeboid microglia 
Amoeboid microglial cells are mainly associated with the developing CNS (Ling and Wong, 1993; 
Dalmau et al., 1997; Ladeby et al., 2005). These microglial cells exhibit a large round cell body 
with few filopodia, which allows them to move easily throughout the neural tissue where they 
fulfill their scavenger role. Amoeboid microglia are able to phagocytose debris, but they do not 
accomplish the same antigen-presenting and inflammatory roles as activated microglia 
(Brockhaus et al., 1996; Cuadros and Navascues, 1998). Once they arrive at their final destination, 
the vast majority of amoeboid microglia differentiates into primitive ramified microglia, while few 
undergo apoptosis (Dalmau et al., 2003; Ladeby et al., 2005). Primitive ramified microglia 
constitute an intermediate state between amoeboid and ramified microglia. They are poorly 
ramified and are found in the brain during the period of enormous microglial proliferation 
(Dalmau et al., 2003; Ladeby et al., 2005). 
Resting / ramified microglia in the normal brain 
Ramified microglia (see Fig. 1.2 A), which form 10-20 % of the total glial population (Raivich et al., 
1999) are found in the intact brain. Their distribution is rather homogeneous but non-overlapping, 
and they show a slow turnover. Their state is often referred to as “resting” (Luo et al., 2010) but it 
was shown that resting microglia actively screen the entire CNS parenchyma with their highly 
motile processes every few hours (h); (Fetler and Amigorena, 2005). Unlike the amoeboid form of 
microglia, the somata of the ramified microglia generally remain fixed (Nimmerjahn et al., 2005). 
Their processes were observed to directly contact astrocytes, neuronal cell bodies, neuronal 
synapses and blood vessels suggesting that in healthy brain, microglia dynamically act together 
with other cortical cells (Nimmerjahn et al., 2005; Wake et al., 2009). Unlike amoeboid or 
activated microglia, resting microglia have no phagocytic activity (Streit et al., 1999) and they 
express low levels of major histocompatibility complex (MHC) antigens and activation markers 
(Tsuchiya et al., 2005). They therefore display very low antigen-presentation capacity. However, 
resting microglia constitutively express a number of surface molecules including cluster of 
differentiation molecule (CD)11b, CD68, F4/80 and Iba1, which are often used to identify 
microglia (Guillemin and Brew, 2004). 
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Fig. 1.2: Progressive change in microglial morphology upon activation.  
Rat hippocampus slice stained with OX-42 (recognizes the rat counterpart of the microglial cell surface antigen 
CD11b and CD11c) at 8 days in vitro after 24 h exposure to 5 μg/ml LPS. All shapes of microglia were found within 
the slice. (A) "Resting", ramified microglia, (B) "reactive", activated microglia, and (C) "phagocytic", macrophage 
microglia. Scale bars: 50 μm (from Huuskonen et al., 2005). 
 
Therefore, it is likely that ramified microglia monitor the well-being of the brain cells and also 
clean the extracellular fluid in order to maintain central homeostasis and an immunologically 
silent environment (Booth and Thomas, 1991; Thomas, 1992; Fetler and Amigorena, 2005). 
Reactive / activated microglia in the injured brain 
In case of trauma or pathogen invasion as well as inflammatory and chronic neurodegenerative 
diseases, resting microglia become gradually activated and undergo morphological as well as 
functional changes (Raivich et al., 1999; Ransohoff, 2007). Indeed, they rapidly switch from their 
ramified shape to a rounded (rod-shape) morphology (see Fig. 1.2 B and C) and 2-3 days after 
injury, their number is increased through mitotic division (Streit et al., 1999; Ladeby et al., 2005). 
Although microglia number predominantly increases due to resident microglia proliferation, a 
process called reactive microgliosis, it was shown that these cells are supplemented by microglia 
from adjacent brain areas as well as by recruited bone marrow-derived cells (Ladeby et al., 2005; 
Simard et al., 2006; Mildner et al, 2007). Upon neuronal death, microglia might acquire a 
macrophage-like morphology with phagocytic activity (see Fig. 1.2 C; Kreutzberg, 1996; Raivich et 
al., 1999). Activated microglial cells migrate into the lesion site, surround damaged or dead cells, 
clear cellular debris by phagocytosis and release inflammatory cytokines (Tanaka et al., 2003; 
Fetler and Amigorena, 2005; Napoli and Neumann, 2009). At the molecular level, there is an up-
regulation or de novo expression of different cell surface receptors, cytokines, growth factors, 
free radicals and NO (Streit, 2000; Mantovani et al., 2004; Ladeby et al., 2005). Moreover, 
microglial activation may result in expression of MHC antigens and costimulatory molecules 
(Hoftberger et al., 2004; Ladeby et al., 2005; Tsuchiya et al., 2005). 
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1.1.3. Characterization of microglia using surface markers 
The characterization of microglia using surface expression markers is difficult, as they share most 
markers with macrophages. However, studies define the following surface marker profile for 
microglia: CD68+, CD45low, CD11b+, CD11chigh, MHC class II+, Iba1+ and F4/80+ (Guillemin and Brew, 
2004). Iba1 is probably the most versatile immunocytochemistry marker for microglial cells 
(Graeber and Streit, 2010). 
1.1.4. Microglial activation 
Microglial cells are responsible for the first line of immune defense in the CNS. The activation of 
microglia is a graded response to a variety of signals or stimuli (see Fig. 1.3; Raivich et al., 1999; 
van Rossum and Hanisch, 2004). Microglia become activated under even minor changes in the 
CNS, including the presence of pathogens, pathogen components and infectious diseases of the 
CNS as well as acute or chronic neurodegenerative diseases (Raivich et al., 1999; Ransohoff, 
2007).  
Pathogens are detected by microglia by the means of pattern recognition receptors (PRRs) 
located on their cell surface (Colton, 2009). These PRRs recognize the so-called pathogen-
associated molecular patterns (PAMPs), which are found only on the cell surface of pathogens. 
Most PRRs are only expressed at low levels on ramified microglia and are up-regulated upon 
microglial activation (Aloisi, 2001). 
The most common activation compound used in vitro to mimic gram-negative bacterial infections 
is the bacterial endotoxin lipopolysaccharide (LPS); (Hanisch, 2002). LPS induces an inflammatory 
reaction in microglia, leading to the production of pro-inflammatory cytokines and chemokines 
(Nakajima et al., 2003), tumor necrosis factor (TNF)-α and nitric oxide synthase-2 (NOS2) (Napoli 
and Neumann, 2009). The Toll-like receptor (TLR)-4 was shown to be a central mediator of the LPS 
induced activation of microglia (Kalis et al., 2003). 
Local tissue damage is also a stimulus able to activate microglia, suggesting that the damage cells 
produce a signal that activates microglia. Indeed, it is known that nucleotides such as adenosine 
triphosphate (ATP) are released by injured neurons and attract microglia via activation of 
purinoceptors (Honda et al., 2001; Haynes et al., 2006). In the presence of apoptotic cells, 
microglia can phagocytose them without triggering an inflammation. Indeed, they release anti-
inflammatory cytokines such as transforming growth factor-β (TGF-β); (Napoli and Neumann, 
2009).  
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Activated microglia share many functions with tissue macrophages, including phagocytosis and 
antigen presentation (in association with MHC class II molecules) to circulating T-cells. They also 
produce a lot of inflammatory cytokines (see Fig. 1.3) like interleukin (IL)-1, IL-6, IL-10, chemokine 
(C-X-C motif) ligand 10 (CXCL10) and TNF-α, chemokines, complement components, reactive 
oxygen intermediates and NO (Liu et al., 1998; Gregersen et al., 2000; Hanisch, 2002; Mack et al., 
2003; Mantovani et al., 2004). It is important to note that microglial activation is a transient and 
self-limited process and usually declines within about one month after injury, even after severe 
traumatic and/or ischemic insults (Streit et al., 1999). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Albeit the absence of injury or damage, microglia become progressively more activated with age. 
Indeed, microglial hypertrophy and rod cell formation can be observed in aged brains. Moreover, 
microglia start to fuse together, forming clusters of cells that are thought to form progressively 
larger aggregates eventually culminating in the formation of senile plaques (Streit and Sparks; 
1997; Luo et al., 2010). 
Inflammatory mediators 
The main communication mode between microglia and other cells of the immune system is the 
synthesis of many different cytokines, which is an inducible process upon request (Hanisch, 2002). 
Cytokines may mediate the recruitment of other microglia and peripheral immune cells and affect 
the activation state of microglia (Hanisch, 2002). Mainly, cytokines are grouped into pro- and anti-
Fig. 1.3: Microglial activation in response to pathological events such as disease or injury.  
Morphology of microglia progressively changes from a ramified to an amoeboid form depending on the degree 
of the injury. In the course of microglial activation, phagocytosis capacity of microglia is enhanced. Upon 
activation, pro-inflammatory molecules are released (modified from Streit, 1999; Kettenmann, 2007). 
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inflammatory mediators. Microglial activation can induce the initial release of both cytokines 
types, and some cytokines can have an autocrine impact on further release activity (Hanisch, 
2002). Essential cytokine systems for microglia include members of IL family, IFNs, TNF and 
relatives, and chemokines (Hanisch, 2002). Different stimuli induce the expression of distinctive 
cytokines in the CNS. To give an example, indirect trauma such as in the facial axotomy model, 
leads to the expression of IL-6 followed by that of TGF-β1 (Raivich et al., 1999). Direct brain injury, 
convulsion and Alzheimer’s disease (AD) typically lead to the additional induction of IL-1β and 
TNF-α. Infectious inflammation due to viral and bacterial meningitis and encephalitis, human 
immunodeficiency virus, malaria and autoimmune diseases, cause the additional synthesis of    
IFN-γ (Raivich et al., 1999). To summarize, the expression pattern of cytokine can be illustrated by 
a pyramid, as increased brain pathology leads to a step by step enrollment of more and more pro-
inflammatory cytokines (Raivich et al., 1999). 
ILs are a group of cytokines which are key signaling molecules for many immune cells including 
microglia. IL-1 is a pro-inflammatory cytokine that exists in two isoforms, IL-1 being mostly cell-
associated and IL-1 being the major soluble form. IL-1 is a crucial microglial effector cytokine and 
plays central role in innate defense and immune response (Hanisch, 2002). IL-1 is released during 
inflammation by activated microglia and invading immune cells. In vitro, it was shown that IL-1 
induces expression of the pro-inflammatory cytokines TNF-α and IL-6 as well as the enzyme 
cyclooxygenase-2 (COX-2) in both astrocytes and microglia (Shaftel et al., 2008). 
IL-4, IL-10, IL-13 and TGF- have anti-inflammatory, immunosuppressive and neuroprotective 
effects, which can be attributed to a down-regulation of pro-inflammatory cytokines production 
by glial cells or to the attenuation of their secondary release actions (Hanisch, 2002). A self-
regulating mechanism may therefore exist, with the potential to control inflammation. 
IFNs are a group of widely expressed cytokines that affect cell growth, immunomodulation and 
communication between cells. They play a major role in the first line of defense against viral 
infections (Hanisch, 2002). Two main types of IFNs exist: type I and type II IFNs. IFN- and IFN- 
are two kinds of type I IFN and are released upon viral infection (Hanisch, 2002). IFN- is the only 
type II IFN and is produced by certain activated T-cells and natural killer cells. In microglia, IFN- 
causes induction and up-regulation of many different cell surface molecules; MHC class I and II, 
intercellular adhesion molecule (ICAM)-I, immune-accessory molecules B7 (CD80/86), leukocyte 
function-associated molecule 1, LPS receptor (CD14), Fc and complement receptors. It also 
induces changes in the proteasome composition, as well as release of cytokines (TNF-α, IL-1, IL-6), 
components of the complement system (C1q, C2, C3, C4), and NO (Hanisch, 2002). 
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1.1.5. Microglial sub-differentiation 
The absence of neurogenesis, the limited regeneration of injured nerves and the vulnerability to 
degenerative conditions has long been considered as the cause of poor recovery from acute 
insults or chronic degenerative disorders in the CNS (Butovsky et al., 2006). However, during the 
last decade, it has been shown that the brain undergoes neurogenesis throughout life to a limited 
extent (Kuhn et al., 1996; Eriksson et al., 1998, Ekdahl et al., 2009). Brain inflammation, which 
activates microglia, strongly attenuates neurogenesis and might play an important role in the 
pathogenesis of chronic neurodegenerative disorders like AD and Parkinson’s disease (PD); 
(Ekdahl et al., 2003). More recent studies have shown, however, that a local and well controlled 
immune response can be beneficial, support survival and promote recovery in the brain, whereas 
an uncontrolled one impairs neuronal survival and repair processes and may lead to autoimmune 
disease (Butovsky et al., 2005). During an inflammatory reaction, the pro-inflammatory process is 
important to permit the elimination of causative infectious, toxic or allergenic agents. However, it 
is important that this pro-inflammatory process, once induced, does not escalate, but is down-
regulated to allow healing (Gratchev et al., 2001). Therefore pro- and anti-inflammatory processes 
have to be activated spatially and temporally in a very precise manner (Goerdt et al., 1999; 
Goerdt and Orfanos, 1999). Microglia activation, which is an indication of brain inflammation, is 
therefore no more seen as being either toxic or protective for neurons. The consequences of their 
activation depend on the balance between the secretion of anti- and pro-inflammatory 
molecules. 
Microglia might be sub-differentiated in vitro in two different subtypes, type I (M1) microglia and 
type II (M2) microglia which represent the extremes of the differentiation spectrum (see Fig. 1.4). 
These two types of microglia differ in terms of receptor expression, cytokine production, effector 
function and cytokine repertoires (see Fig. 1.4; Mantovani et al., 2004). The M1 subtype is similar 
to that of the classically activated pro-inflammatory microglia whereas the M2 subtype 
corresponds to the alternatively activated anti-inflammatory microglia (Stein et al., 1992; 
Michelucci et al., 2009, Kigerl et al., 2009). The M1 subtype are triggered to respond to microbial 
compounds like LPS or pro-inflammatory cytokines like IFN-γ and T helper cell type (Th) 1-derived 
lymphokine (Mantovani et al., 2004; Michelucci et al., 2009). Their activation induces the 
production of pro-inflammatory cytokines such as IL-1, IL-12 and TNF-α, free radicals like NO and 
superoxide anions (Goerdt and Orfanos, 1999). Although these molecules are essential for the 
defense of the brain, their expression also causes a lot of collateral damage to the cells and 
tissues (Ding et al., 1988). 
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Microglia might be activated into the M2 subtype in the presence of a variety of Th2 lymphocyte 
products such as IL-4, IL-10, IL-13 and TGF-β (Kigerl et al., 2009; Goerdt and Orfanos, 1999). They 
have anti-inflammatory properties and preferentially express receptors involved in endocytosis or 
phagocytosis such as macrophage mannose receptor and scavenger receptor type 1 (ScavR1) 
(Stein et al., 1992; Goerdt and Orfanos, 1999). They are important to mediate tolerance, to 
downregulate inflammation and to protect the tissues against oxidative damage (Goerdt et al., 
1999; Ghassabeh et al., 2006). It was recently shown that they have improved clearance function 
of oligomeric amyloid-β (Aβ) (Shimizu et al., 2008).  
These two types of microglial cells permit to balance pro- and anti-inflammatory immune 
reactions in the brain. Recent in vitro studies have shown that microglia activated by IFN-γ (M1) 
prevent oligodendrogenesis and neurogenesis whereas microglia activated by IL-4 (M2) induced 
both (Butovsky et al., 2006). Moreover, Kigerl and colleagues have claimed that the polarization 
of resident macrophages and infiltrating blood monocytes into M2 subtype could limit secondary 
inflammatory-mediated injury and therefore promote CNS repair (Kigerl et al., 2009). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.4: Overview of microglial sub-differentiation into M1 or M2 subtype.  
Microglia polarize and acquire different functional properties in response to environment derived signals. IFN-γ 
and LPS drive M1 polarization, with potentiated cytotoxic and anti-tumoral properties whereas M2 microglia 
drive Th2 response. 
Abbreviations: DTH, delayed-type hypersensitivity; iNOS, inducible nitric oxide synthase;                                            
LPS, lipopolysaccharide; MR, mannose receptor; RNI, reactive nitrogen intermediates; ROI, reactive oxygen 
intermediates; SRs, scavenger receptors (modified from Mantovani et al., 2004). 
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1.2. Embryonic stem cells 
An embryo is formed and develops through a process called embryogenesis. The fertilization of 
the egg gives rise to a zygote, which possesses the ability to generate the entire organism. This 
capacity is known as totipotency and is retained up to the eight-cell stage of morula (Wobus and 
Boheler, 2005). Subsequent cell differentiation gives rise to the formation of the blastocyst 
composed of the inner cell mass (ICM); (or embryoblast) which forms the embryo, and the outer 
layer of cells (or trophoblast), which later forms the placenta. The cells of inner cell mass are 
pluripotent as they retain the ability to form all the cell types of the embryo (Wobus and Boheler, 
2005).  
In 1981, the group of Evans and Kaufman succeeded in cultivating mouse pluripotent stem cells 
from blastocysts (see Fig. 1.5; Evans and Kaufman, 1981). These cells, called embryonic stem cells 
(ESC), originated from the ICM and could be maintained in vitro on a feeder layer of inactivated 
mouse embryonic fibroblasts (MEF) without losing their differentiation potential. To prove the 
pluripotency of these cells, mouse chimeras were created by injection into blastocysts and it was 
shown that ESC could contribute to all cell lineages including the germ line (Bradley et al., 1984). 
In vitro, murine ESC lines have an almost unlimited proliferation capacity and retain the ability to 
contribute to all cell lineages. Moreover, they conserve a relatively normal and stable karyotype, 
even during further passaging (Evans and Kaufman, 1981; Smith, 2001). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.5: Developmental origin of pluripotent embryonic stem cell lines of the mouse.  
The scheme demonstrates the derivation of embryonic stem cells between embryonic day E2 to E3.5. ESCs are 
derived from the ICM of blastocysts (Modified from Wobus and Boheler, 2005). 
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The inactivated MEF layer is used because it supplies important factors either to promote self-
renewal or to inhibit differentiation of ESCs (Wobus and Boheler, 2005). For example, it was 
shown that leukemia inhibitory factor (LIF), a soluble glycoprotein of the IL-6 class cytokine has 
both effects on ESCs (Williams et al., 1988). It was shown that LIF supplementation to the culture 
media has little effect on growth rates, but it significantly altered the probability of cells 
undergoing self-renewal versus differentiation (Zandstra et al., 2000).  
1.2.1. In vitro differentiation potential of ESCs 
During mouse embryogenesis, the ICM proliferates rapidly and gives rise to the primitive 
ectoderm from which three germ layers are derived: endoderm, mesoderm and ectoderm. These 
three germ layers give rise to all tissue and organs of the developing embryo (Wobus and Boheler, 
2005). 
Differentiation of ESCs in vitro is induced by triggering embryoid body (EB) formation in the 
absence of self-renewal signals provided by feeder cell layers or LIF (Wobus and Boheler, 2005). 
Once differentiation has begun, spontaneous development of cells representing the three primary 
germ layers inside the EBs occurs. These EBs are then transferred to culture tissue dishes to allow 
continued differentiation into a range of specialized cell types including cardiac, smooth and 
skeletal muscle as well as hematopoietic, pancreatic, hepatic, lipid, cartilage, or neuronal and glial 
cells (Wobus and Boheler, 2005). A carefully chosen combination of signal proteins can be used to 
induce the differentiation of the desired cell type. 
1.3. Embryonic stem cell derived microglial precursors (ESdM) 
Microglia were shown to be major players in some neurodegenerative diseases like AD, PD and 
multiple sclerosis (MS) (Streit, 2004). Therefore, the idea to use them in therapy approaches for 
such diseases is pretty attractive. One major problem is the difficulty to obtain sufficient amounts 
of primary microglia by traditional procedures for biochemical analysis and in vivo experiments 
(Napoli et al., 2009). Classical procedures to obtain primary microglia are either the isolation of 
microglia from mixed glial cultures derived from early mouse brain tissue or the isolation of 
microglia directly by flow cytometry (Ford et al., 1995; Havenith et al., 1998). As these procedures 
are very time consuming, many researchers have used oncogenically transformed microglial cell 
lines like BV-2 or N9 instead of primary microglia (Blasi et al., 1990; Bocchini et al., 1992). The 
problem with these cell lines is that the original microglial characteristics and functions might be 
affected due to the oncogenical transformations (Horvath et al., 2008). 
 
E2 – E3.5 
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To avoid all these problems, Napoli and colleagues have developed a protocol to differentiate 
microglia from mouse ESCs (Napoli et al., 2009; Beutner et al., 2010) by modification of a protocol 
for neuronal differentiation (Lee et al., 2000). This protocol provides a tool to obtain unlimited 
numbers of ESdM without any oncogenic modification. The protocol contains five main steps;     
(1) culture of ESCs on a MEF layer in LIF containing medium, (2) formation of EBs in non adherent 
dishes followed by transfer into adherent dishes for EBs differentiation, (3) selection of neuronal 
precursor cells, (4) expansion of these neuronal precursor cells and (5) differentiation into 
microglial precursor cells. In total, approximately seven weeks are necessary to obtain ESdM.   
It was shown that ESdM display on average a doubling time of about 20 h. ESdM express 
microglial markers like Iba1, CD11b, CD45, CD86 (B7.2), α4 and β1 integrins and F4/80, but they 
are negative for stem cell markers CD117 (cKit) and CD34. Moreover, and like primary microglia, 
ESdM display little or very low constitutive expression of MHC class II. The profile of cytokines 
expression of ESdM resembles that of primary microglia and BV-2 after LPS and IFN-γ stimulation. 
ESdM express the receptor CX3CR1 and are able to migrate toward the chemokines CX3CL1 in a 
way similar to primary microglia. Upon stimulation with LPS, ESdM are able to phagocyte 
microsphere beads, which is an important functional aspect of microglia. Moreover, after in vivo 
transplantation, ESdM engraft next to injection sides within the parenchyma of the cortex and 
hippocampus (Napoli et al., 2009; Beutner et al., 2010). RNA microarray of 44 000 genes was also 
performed to compare the gene expression profile of primary microglia to ESdM. 20 000 gens 
were found to be expressed in primary microglia and ESdM. Of these expressed genes, over 19 
000 were co-expressed by primary microglia and ESdM, meaning that ESdM have a similar genetic 
profile as primary microglia (data obtained by Clara Beutner, unpublished).  
Thus, the differentiation of ESCs into ESdM is an ideal tool to obtain sufficient cells number for 
biochemical analysis and in vivo experiments. Moreover, ESdM are an adequate substitute for 
primary microglia as they display properties alike of primary microglia.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction  18 
1.4. Aim of the study 
One major problem one has to face when working with microglia is the difficulty to obtain 
sufficient amounts of primary microglia by isolation and enrichment from mixed glial cultures 
derived from early mouse brain tissue or by isolation of microglia directly by flow cytometry (Ford 
et al., 1995; Havenith et al., 1998) for biochemical analysis and in vivo experiments. Napoli and 
colleagues developed a protocol to differentiate microglia from mouse ESCs (Napoli et al., 2009; 
Beutner et al., 2010). ESdM were shown to be an appropriate substitute to primary microglia 
(Napoli et al., 2009; Beutner et al., 2010) and using this protocol, it is possible to obtain a high 
number of ESdM and therefore, biochemical analysis and in vivo experiments are possible. 
 
Microglia can have both, cytotoxic and regenerative effects in the CNS depending on their stage 
of polarization. It is believe that these two effects are a consequence of the polarization of 
microglia either into NO producing microglia (M1) or into phagocytically active microglia (M2). 
Moreover, it was shown that it is possible to polarize in vitro macrophages into cytotoxic cells by 
stimulating them with pro-inflammatory molecules such as IFN-γ or LPS or into regenerative cells 
by stimulation with anti-inflammatory cytokines such as IL-4 or IL-13.  
 
The aim of this study was to polarize ESdM into type I microglia (M1; cytotoxic) or into type II 
microglia (M2; regenerative) in order to obtain two stable cell lines. Indeed, it would be of great 
interest to have lines of polarized ESdM in a sufficient amount and to use them as a natural cell-
based vehicle for gene therapy of neurological disorders. 
The questions addressed in this work are (1) whether ESdM can be polarized in vitro into M1 
versus M2 subtypes, and (2) to find the chemokines and cytokines that are differentially 
expressed in these two subtypes. The long-term aim of this project is to understand the influence 
of polarized microglia on the experimental autoimmune encephalomyelitis mice model and to see 
whether it would be possible to culture ESdM in vitro, polarize them in a beneficial cell type and 
use them for cell therapy approaches of neuroinflammatory diseases. The last aspect was not a 
part of this study. 
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2. MATERIALS AND METHODS 
2.1. Materials 
2.1.1. Buffers and solutions 
 4 % Paraformaldehyde (PFA), pH 7.3 
 20 g PFA  Sigma, Germany 
 30 ml NaOH Roth, Germany 
 50 ml PBS (10x)  Gibco, Germany   
 up to 1 liter ddH2O   Roth, Germany 
 Quantitative real time PCR mix 
 3 μl cDNA (200 ng/μl)    
 12.5 μl SYBR Green Master Mix (2x)  Applied Biosystems, USA 
 4 μl Primer mix (20 pmol/μl)   Eurofins MWG, Germany 
 5.5 μl ddH2O  Roth, Germany 
 Reverse transcription (RT) mix 
5 μg Total RNA   
1 μl Hexanucleotide Mix (10x)   Roche, Germany 
1 μl dNTP mix (10 mM)   Sigma, Germany 
2 μl DTT mix (10 mM)   Invitrogen, Germany 
4 μl 5x RT 1st Strand Buffer   Invitrogen, Germany 
1 μl Superscript III RT (200 U/ml)  Invitrogen, Germany 
up to 20 μl ddH2O    Roth, Germany 
 
2.1.2. Cell culture media  
 Differentiation medium 
DMEM 4.5 g/l D-glucose Gibco, Germany 
15 % vol/vol Fetal bovine serum (FBS) Gibco, Germany 
2 mM L-alanin-L-glutamine (GlutaMAX) Gibco, Germany 
1 mM Sodium-pyruvate  Gibco, Germany 
0.1 mM Non-essential amino acids  Gibco, Germany 
0.05 mM β-mercaptoethanol  Gibco, Germany 
 ESC medium 
DMEM 4.5 g/l D-glucose Gibco, Germany 
15 % vol/vol FBS  Gibco, Germany 
2 mM GlutaMAX  Gibco, Germany 
1 mM Sodium-pyruvate  Gibco, Germany 
0.1 mM Non-essential amino acids  Gibco, Germany 
0.05 mM β-mercaptoethanol  Gibco, Germany 
1 µg/l Recombinant murine LIF  Chemicon, USA 
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 ITSFn medium 
DMEM/F12 (1:1)   Gibco, Germany 
25 µg/ml Insulin  Sigma, Germany 
30 nM Sodium-selenit  Sigma, Germany 
50 µg/ml Transferrin  Sigma, Germany 
5 µg/ml Fibronectin (add freshly)  Sigma, Germany 
 MEF medium 
DMEM 4.5 g/l D-glucose  Gibco, Germany 
10 % vol/vol FBS  Gibco, Germany 
2 mM L-glutamine  Gibco, Germany 
1 mM Sodium-pyruvate  Gibco, Germany 
0.1 mM Non-essential amino acids  Gibco, Germany 
 N2 medium 
DMEM/F12 (1:1)   Gibco, Germany 
1 x N2 supplement (5 ml)  Gibco, Germany 
0.48 mM L-glutamine  Gibco, Germany 
5.3 µg/ml D-glucose (45 %)  Sigma, Germany 
100 µg/ml Penicillin/Streptomycin  Gibco, Germany 
 
2.1.3. Other reagents 
  Bovine serum albumin (BSA) Sigma, Germany  
  4’,6-diamidino-2-phenylindole (DAPI) Sigma, Germany 
  Dimethyl Sulfoxide (DMSO) Sigma, Germany 
  DPBS (1x) Gibco, Germany 
  Fibroblast growth factor (FGF)2, recombinant human  R&D, Germany 
  Fibronectin from bovine plasma  Sigma, Germany 
  Fluoresbrite Polychromatic Red Microspheres  Polysciences, Germany 
  Gelatine Fluka, Germany 
  Granulocyte macrophage-colony stimulating factor  
  (GM-CSF), recombinant mouse (rm) Invitrogen, Germany 
  Hexanucleotide Mix (10X)  Roche, Germany 
  IFN-γ, rm  R&D, Germany 
  IL-4, rm Sigma, Germany 
  Laminin, natural mouse  Invitrogen, Germany 
  LPS Sigma, Germany 
  Normal goat serum (nGS) Sigma, Germany 
  Poly-L-lysine (PLL) Sigma, Germany 
  Reverse transcriptase hexamer  Roche, Germany 
  SuperScript® III Platinum® Two-Step qRT-PCR Kit  Invitrogen, Germany 
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  Transferrin bovine  Sigma, Germany 
  TritonX-100  Sigma, Germany 
  Trypsin-EDTA (0.25 %) Gibco, Germany 
 
 
 
2.1.4. Antibodies 
Tab. 2.1: Primary antibodies directed against mouse used for flow cytometry.  
Antibody Host Conjugation Dilution Company 
CD11b  rat  biotin  1:200 BD Biosciences, Germany 
CD11c rat  biotin  1:200 BD Biosciences, Germany 
CD16/CD32 for Fc-Block  rat  -   1:100 BD Biosciences, Germany 
CD16/CD32 for Fc-Block  rat  biotin  1:100 BD Biosciences, Germany 
CD16/CD32 rat  biotin  1:200 BD Biosciences, Germany 
CD29 rat -  1:200  BD Biosciences, Germany 
CD34 rat biotin 1:50 AbD Serotec, Germany 
CD45  rat  biotin 1:200 BD Biosciences, Germany 
CD49d rat -  1:200 BD Biosciences, Germany 
CD64 rat -  1:200 R&D Systems, Germany 
CD68 rat -  1:50 AbD Serotec, Germany 
CD86 (B7.2) rat  biotin   1:200 BD Biosciences, Germany 
CD117 (c-kit) rat biotin  1:200 BD Biosciences, Germany 
CD206 rat -  1:100 Acris, Germany 
F4/80 rat biotin 1:10 AbD Serotec, Germany 
Scavenger Receptor B1 rabbit -  1:200 Thermo Scientific, Germany 
TREM-2b rat -  1:200 R&D Systems, Germany 
I-A/I-E (MHC class II) rat biotin 1:200 BD Biosciences, Germany 
Isotype IgG2a, κ rat -  1:200 BD Biosciences, Germany 
Isotype IgG2b, κ rat -  1:200 BD Biosciences, Germany 
 
 
 
 
 
Tab. 2.2: Primary antibodies directed against mouse used for immunocytochemistry.  
Antibody Host Dilution Company 
Arginase I (V-20)  goat   1:100 Santa Cruz Biotechnology, USA 
β-III-tubulin  mouse   1:500  Sigma, Germany 
CD11b  rat   1:500  BD Biosciences, Germany 
CD16/CD32  rat   1:500  BD Biosciences, Germany 
CD29  rat   1:500  BD Biosciences, Germany 
CD45  rat   1:500 BD Biosciences, Germany 
CD86  rat   1:100 BD Biosciences, Germany 
CD206  goat   1:100 R&D Systems, Germany 
GFAP  rabbit   1:100 DAKO, USA 
Iba1  rabbit   1:500 Wako, Germany 
iNOS  rabbit   1:500 BD Biosciences, Germany 
Nestin  mouse   1:200 Millipore, Germany 
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Tab. 2.3: Secondary antibodies used for flow cytometry. 
Antibody Host Directed against Dilution Company 
PE goat rat  1:300 Jackson ImmunoResearch, USA 
PE goat rabbit  1:300 Jackson ImmunoResearch, USA 
PE - streptavidin 1:300 Jackson ImmunoResearch, USA 
 
Tab. 2.4: Secondary antibodies used for immunocytochemistry. 
Antibody Host Directed against Dilution Company 
Alexa488 goat mouse 1:500 Invitrogen, Germany 
Alexa488 goat rabbit 1:500 Invitrogen, Germany 
Alexa488 goat rat  1:500 Invitrogen, Germany 
Cy3 goat mouse 1:500 Jackson Immunoresearch, USA 
Cy3 goat rabbit 1:500 Jackson Immunoresearch, USA 
Cy3 goat rat  1:500 Jackson Immunoresearch, USA 
 
 
 
2.1.5. Primer sequences for quantitative real time polymerase chain reaction (qRT-PCR) 
Tab. 2.5: Primers used for qRT-PCR. All primers were purchased from Eurofins MWG, Germany. 
 
Target gene Forward sequence Reverse sequence 
GAPDH 5’ - AAC TTT GGC ATT GTG GAA GG - 3’ 5’ - ACA CAT TGG GGG TAG GAA CA - 3’ 
M1 
iNOS 5’ - AAG CCC CGC TAC TAC TCC AT - 3’ 5’ - GCT TCA GGT TCC TGA TCC AA - 3’ 
TNF-α 5’ - TCT TCT CAT TCC TGC TTG TGG - 3’ 5’ - AGG GTC TGG GCC ATA GAA CT - 3’ 
CXCL10 5’ - CAT CCA CCG CTG AGA GAC AT - 3’ 5’ - CTC AGA CCC AGC AGG ATG AG - 3’ 
M2 
Arginase 1 5’ - CAG AAG AAT GGA AGA GTC AG - 3’ 5’ - CAG ATA TGC AGG GAG TCA CC - 3’ 
Ym(1/2) 5’ - CAT TCA GTC AGT TAT CAG ATT CC - 3’ 5’ - AGT GAG TAG CAG CCT TGG - 3’ 
IL-10 5’ - AAG GAC CAG CTG GAC AAC AT - 3’ 5’ - TCT CAC CCA GGG AAT TCA AA - 3’ 
 
 
2.1.6. Equipment  
  BD FacsCalibur, flow cytometer BD Bioscience, Germany 
  Axioskop 2, microscope  Zeiss, Germany 
  Axiovert 40 CFL, microscope  Zeiss, Germany 
  Canon Powershot G9, photo camera  Canon, Japon 
  Eppendorf Mastercycler epgradient S  Eppendorf Germany 
  Thermocycler T3  Biometra, Germany 
  GENios Pro, multiplate reader Tecan, Switzerland 
  NanoDROP 1000, photospectrometer Thermo Scientific, Germany 
 
 
2.1.7. Software 
  Adobe Photoshop 7.0 Adobe, USA 
  Axiovision 4.6.3   Carl Zeiss Imaging Solutions, Germany 
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  Cellquest Pro  BD Biosciences, USA 
  EndNote X1   Thomson ISI ResearchSoft, USA 
  FlowJo 6.4.7   Tree Star, USA 
  NanoDrop 1000 V3.7.1 Thermo scientific, Germany 
  Olympus FluoView 1.4  Olympus, Germany 
  Openlab 4.0.1  Improvision, Germany 
  SPSS PASW Statistics 18 IBM, USA 
2.1.8. Kits  
  RNeasy Mini, RNA isolation kit  Qiagen, Germany 
  Quantikine, mouse IL-10, ELISA kit  R&D Systems, Germany 
  Quantikine, mouse CXCL10, ELISA kit  R&D Systems, Germany 
  Griess Reagent System  Promega, USA 
 
 
2.2. Methods 
2.2.1. Generation of murine embryonic stem cell derived microglial precursors (ESdM) 
An ESC line from C57BL/6-ATCC mice was used for the differentiation into ESdM. In vitro 
differentiation of ES cells into ESdM was carried out using a modified five-step protocol originally 
designed to obtain neurons (see Fig. 2.1; Lee et al., 2000; Tsuchiya et al., 2005; Napoli et al., 2009; 
Beutner et al., 2010). ESCs were first cultured on irradiated feeder cells (derived from MEF) which 
provide self-renewal signals. ESCs colonies were then trypsinized and single-cells were cultured on 
gelatine-coated tissue culture dishes in a LIF containing ESC medium to avoid differentiation 
(stage 1). After one day, cells were washed three times with phosphate-buffered saline (PBS), 
trypsinized and centrifuged (1300 rpm, 3 minutes (min), 4°C). Cells were resuspended in 
differentiation medium (same as ESC medium but without LIF) and single cells were transferred 
into non adherent bacterial culture dishes to induce EBs formation (stage 2). After four days, the 
resulting EBs were plated onto gelatine-coated tissue culture dishes to induce differentiation. Two 
days later, selection of nestin positive cells was initiated by replacing the differentiation medium 
by ITSFn medium (stage 3). After six days of selection, cells were washed once with PBS and 
expansion of nestin positive cells was initiated in N2 medium supplemented with 5 ng/ml basic 
fibroblast growth factor (bFGF) and 1 µg/ml laminin (stage 4). After six days of expansion, 
microglial differentiation was induced by removing bFGF and culturing cells for four days in N2 
medium supplemented with 1 µg/ml laminin. This was followed by more than thirty days of 
culture in N2 medium (stage 5). When the first cells with microglia-like morphology appeared in 
the culture dishes (approximately 3 weeks after growth factors removal), 20 ng/ml of rm GM-CSF 
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were added to fresh medium to enhance microglial proliferation (Esen and Kielian, 2007; Liva et 
al., 1999; Giulian and lngeman, 1988). During the whole differentiation procedure, cells were kept 
in 5 % CO2 at 37°C.  
 
2.2.2. Separation and maintenance of ESdM  
First cells with microglia-like morphology were observed three weeks after removal of growth 
factors. When enough number of ESdM were observed in the dishes, they were manually isolated 
from the differentiation dishes and were cultured on tissue culture dishes pre-coated with PLL in 
N2 medium supplemented with 10 ng/ml rm GM-CSF. Medium was changed every third day. For 
further passaging, cells were detached with a cell scraper at 80 % confluency and were kept in N2 
medium in 5 % CO2 at 37°C. Cells could be frozen in N2-medium supplemented with 10 % DMSO 
and 40 % FBS and were thawed without losing their phenotype.  
2.2.3. Early treatment of ESdM with IFN-γ and LPS to obtain ESdM with inflammatory 
background 
One day after the manual isolation of ESdM, cells were treated with rm IFN-γ (250 U/ml) and LPS 
(250 ng/ml) for 24 h. Cells were then washed with PBS and cultured in N2 medium. ESdM were 
treated in the same way two more times at two week interval each. After these three treatments, 
cells were cultured like normal ESdM (see section 2.2.2) and used for different experiments. 
These cells were called ESdM with inflammatory background. 
2.2.4. Sub-differentiation of ESdM and ESdM with inflammatory background into M1 and 
M2 subtypes 
ESdM obtained by the modified five-step protocol described above were used for the sub-
differentiation into M1 or M2 subtype. Both, normal ESdM and ESdM with inflammatory 
background were utilized for the sub-differentiation. The molecules used to induce M1 or M2 
subtype were rm IFN-γ + LPS or rm IL-4, respectively. 
Fig. 2.1: General scheme of the modified five-step method used to differentiate ESCs into ESdM. 
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Indeed, it is known that ESdM in the presence of rm IFN-γ will mostly adopt a M1 phenotype 
whereas in the presence of rm IL-4 they will mostly adopt a M2 phenotype (Mantovani et al., 
2004; Michelucci et al., 2009). Different culture conditions were tried in order to obtain these two 
different subtypes (see Tab. 2.6). In general, concentrations of pro- and anti-inflammatory 
molecules and incubation times were modified according to the results obtained and to the 
investigation method used in order to optimize the stimulation protocol. Once, the addition of 
protein tyrosine phosphatase Src homology phosphatase-1 (SHP-1) was tested because it was 
shown to act as a negative regulator of the Fcγ receptor mediated phagocytosis (Kant et al., 2002; 
Christophi et al., 2008). Moreover, rm IL-13 was tested together with rm IL-4, as it is known that 
rm IL-13 also induces a M2 phenotype in cells (Martinez et al., 2009).  
Different methods were used to assess the phenotype of the stimulated cells (for complete 
method protocols, see sections 2.2.5 to 2.2.10): 
 Flow cytometry: 
Flow cytometric analysis was performed to assess the expression of CD64 and CD16/CD32 that 
should be highly expressed by M1 polarized cells and CD206, ScavR1 and triggering receptor 
expressed on myeloid cells 2 (TREM2), which should be highly expressed by M2 cells. 
 qRT-PCR: 
qRT-PCR was used to detect and quantify the expression of inducible nitric oxide synthase (iNOS), 
CXCL10 (also called IP-10) and TNF-, which are highly expressed by M1 cells and of arginase type 
1 (Arg-1), Ym(1/2) and IL-10 that are highly expressed by cells of the M2 subtype. 
 Immunocytochemistry: 
Immunocytochemistry was used to analyze the expression of three different M1 surface markers: 
CD86, iNOS, CD16/CD32 and of two M2 markers; Arg-1 and CD206. 
 Phagocytosis assay: 
The phagocytosis capacity of ESdM upon M1 or M2 stimulation was assessed as it is known that 
during microglial activation, the phagocytosis ability of debris, dead cells and Aβ peptide is 
enhanced. Moreover, alternatively activated microglia have a better phagocytic capacity 
compared to M1 sub-polarized cells (Michelucci et al., 2009). 
 
 ELISA: 
Presence of CXCL10 and IL-10 was determined in the medium of the cultured cells upon M1 or M2 
treatment using sandwich ELISA kits. 
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 Griess assay: 
Griess Reagent System assay was used to measure nitrite (NO2
-) in the culture medium of cells 
after pro- or anti-inflammatory treatment. Nitrite is one of the two primary, stable and 
nonvolatile breakdown products of NO, known to be secreted by M1 polarized cells. 
 
 
 
 
 
Condition For sub-differentiation into M1 For sub-differentiation into M2 Technique used 
1 rm IFN-γ (100 U/ml) + LPS (5 ng/ml) for 24 h rm IL-4 (20 ng/ml) for 48 h Flow cytometry 
2 
rm IFN-γ (100 U/ml) + LPS (5 ng/ml) 
+ SHP-1 (0.4 nM) for 24 h 
rm IL-4 (20 ng/ml) for 48 h Flow cytometry 
3 rm IFN-γ (500 U/ml) + LPS (500 ng/ml) for 24 h rm IL-4 (20 ng/ml) for 48 h Flow cytometry 
4 
Primed with LPS (10 ng/ml) for 24 h and 
then add rm IFN-γ (200 U/ml) for 24 h 
rm IL-4 (20 ng/ml) for 48 h Flow cytometry 
5 rm IFN-γ (100 U/ml) + LPS (5 ng/ml) for 24 h 
rm IL-4 (40 ng/ml) for 48 h 
Flow cytometry 
qRT-PCR 
Phagocytosis assay 
ELISA 
Griess assay 
6 rm IFN-γ (100 U/ml) + LPS (250 ng/ml) for 24 h 
rm IL-4 (40 ng/ml) for 48 h 
Phagocytosis assay 
7 rm IFN-γ (100 U/ml) + LPS (5 ng/ml) for 24 h 
rm IL-4 (20 ng/ml) every 24 h for 
48 h 
Immunocytochemistry 
qRT-PCR 
8 rm IFN-γ (100 U/ml) + LPS (5 ng/ml) for 24 h 
rm IL-4 (20 ng/ml) 
+ rm IL-13 (40 ng/ml) for 72 h 
ELSIA 
9 rm IFN-γ (100 U/ml) + LPS (5 ng/ml) for 24 h 
rm IL-4 (20 ng/ml) 
+ rm IL-13 (20 ng/ml) for 24 h 
qRT-PCR 
10 rm IFN-γ (100 U/ml) + LPS (5 ng/ml) for 24 h rm IL-4 (40 ng/ml) for 24 h 
ELSIA 
qRT-PCR 
11 rm IFN-γ (200 U/ml) + LPS (50 ng/ml) for 72 h rm IL-4 (40 ng/ml) for 48 h Griess assay 
 
 
 
 
 
2.2.5. Immunocytochemistry of cultured cells  
For immunocytochemistry, cells were washed three times with PBS, fixed in 4 % PFA for 10 min, 
washed again three times with PBS and blocked for 30 min using a solution containing 10 % BSA,  
5 % nGS and 0.1 % Triton X. Cells were then immunostained with various primary antibodies (see 
Tab. 2.2) overnight at room temperature. The next day, cells were washed three times for 5 min 
with PBS and were immunostained with the corresponding secondary antibody (see Tab. 2.4) for 
30 min at room temperature followed by washing three times for 5 min with PBS. Nuclei of 
Tab. 2.6: Conditions used for the sub-differentiation of ESdM into M1 and M2 subtypes. 
For each condition, a list of the methods used to investigate the phenotype of the treated cells is given. Cells 
cultured only in N2 medium were used as control in each case. 
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immunostained cells were then labeled for 30 seconds (s) with DAPI. Samples were covered using 
Moviol and were analyzed using fluorescent microscope (Axioskop2, Zeiss). 
2.2.6. Flow cytometry analysis 
Cells were manually detached from the dishes using a cell scraper and washed once with PBS. 
Cells were first incubated for Fc-receptor blockade with a rat monoclonal antibody directed 
against CD16/CD32 (see Tab. 2.1). Afterwards, cells were stained with various primary antibodies 
(see Tab. 2.1) on ice for 1 h. Samples were then washed two times with PBS and were incubated 
with the corresponding secondary antibody (see Tab. 2.3) for 30 min in dark and on ice, followed 
by two times of washing with PBS. Isotype-matched control antibodies and non-stained cells were 
used as negative controls. Acquisition was done with a FACSCalibur flow cytometer and the 
analysis by using FlowJo Software.  
2.2.7. Analysis of cytokine gene transcripts by qRT-PCR  
Total RNA was isolated from cultured cells using RNeasy Mini Kit according to the manufacturer’s 
instructions. Total RNA was reverse-transcribed using SuperScript III Reverse Transcriptase and 
hexamer random primers according to the manual. cDNA was quantified using a NanoDrop 
photospectrometer and stored at the concentration of 200 ng/l  at – 20°C. 
qRT-PCR was carried out using specific primers (see Tab. 2.5). For each investigated transcript, a 
master mix of the following reaction components was prepared to the indicated                          
end-concentration: forward primer (0.8 pmol/l), reverse primer (0.8 pmol/l) and 12.5 µl Power 
SYBR Green PCR Master mix (1x). The reverse transcription reaction was performed in a total 
volume of 25 l composed of 22 l of master mix and 3 l (24 ng/l) of cDNA in a 96-well reaction 
plate. Optical adhesive covers were used to seal the wells. After centrifugation, PCR was 
performed using an Eppendorf epgradient S Mastercycler with the following program:  
 
 
 
For standardization of quantification, glyceraldehydes-3-phosphate dehydrogenase (GAPDH) was 
amplified simultaneously. Specificity of amplification was confirmed via analysis of the melting 
curves. Quantification was carried out using the delta-CT method. 
 
Cycle number Denaturation Annealing Extension 
1 95°C for 10 min   
2 - 40 95°C for 30 s 57.5°C for 30 s 72°C for 45 s 
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2.2.8. Beads phagocytosis assay 
For in vitro beads phagocytosis assay, 60 000 cells were seeded on a PLL-coated 6 well cell culture 
plate. Next day, cells were treated using M1 or M2 stimulation (see Tab. 2.6). 10 µl of labeled 
microsphere beads were added to the 2 ml of N2 medium in each well for 1.5 h. Cells were then 
washed three times with PBS, trypsinized, centrifuged and resuspended in PBS. Analysis was 
performed using flow cytometry. Only cells that phagocytosed more than one bead were taken 
into consideration. 
2.2.9. Quantikine ELISA 
For the quantitative determination of IL-10 and CXCL10 in the cell culture supernatants, cells were 
seeded into 10 cm tissue culture dishes at a density of 1 million cells per dish. Cells were treated 
with M1 or M2 treatment (see Tab. 2.6) and after that, culture supernates were collected. The 
assays were done according to the manufacturer’s instructions. Reading was performed using a 
multiplate reader.  
For data analysis, a standard curve was created with the optical density obtained from the 
measurement of known cytokine concentrations. Thereafter, concentrations of the cytokine for 
the different conditions were taken from the standard curve. 
2.2.10. Griess Reagent System 
The Griess Reagent System assay allows measuring nitrite, which is a stable and nonvolatile 
breakdown product of NO. To perform the assay, 1 million cells were seeded into 10 cm tissue 
culture dishes. Cells were treated with M1 or M2 treatment (see Tab. 2.6) and after that, culture 
supernatants were collected. The assay was done according to the manufacturer’s instructions. A 
multiplate reader was used for the reading.  
To analyze the data, a standard curve was build using the optical density obtained from the 
measurement of known nitrite concentrations. Thereafter, concentrations of the nitrite in the 
case of the different conditions were read from the standard curve. 
2.2.11. Statistical analysis 
Data are presented as mean ± range of two independent experiments or as mean ± SEM of three 
independent experiments. Data were analyzed by multivariate ANOVA using SPSS computer 
software. 
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3. RESULTS 
3.1. ESdM are efficiently derived from mouse ESCs under standard conditions 
The number of primary microglia obtained by standard methods is very limited and therefore 
these techniques are not suitable for biochemical analysis and in vivo experiments. Napoli and 
colleagues (Napoli et al., 2009) modified a protocol originally developed for neuronal 
differentiation (Lee et al., 2000) into an efficient protocol for microglial precursor cell line 
differentiation from murine ESCs.  
ESCs from C57BL/6-ATCC mice were cultured in a LIF containing medium on a MEF layer to avoid 
differentiation. ESCs formed typical cellular colonies after approximately four days of culture    
(see Fig. 3.1 A). After dissociation of the ESCs colonies, EBs formation was induced on non coated 
petri dishes in a LIF free medium. EBs were round aggregates of cell with various size depending 
on the number of cells that constituted them (see Fig. 3.1 B). After four days, EBs were plated in 
cell culture dishes and cells expanded out of these EBs in ITSFn medium (see Fig. 3.1 C) and 
progressively invaded fast into all free areas of the dishes. In the next stage, a high number of 
nestin positive cells (see Fig. 3.2 A and B) were found in the dishes and expanded in the presence 
of laminin and bFGF (see Fig. 3.1 D). After six days, bFGF was withdrawn to induce differentiation 
of nestin positive cells into neuronal precursor cells and four days later, laminin was also removed 
from the culture medium. 7 days after bFGF removal, cells positive for the neuronal β-III-tubulin 
marker, the microglial CD45 marker as well as the astrocytic marker GFAP were found in the 
mixed culture (see Fig. 3.2 C, D, E and F). First cells with microglia-like phenotype (rounded and 
shiny) were observed at day 19 of stage 5 (see Fig. 3.1 E). These cells were stained with Iba1      
(see Fig. 3.2. G and H) and started to proliferate forming small clusters between the other cells. 
Cell medium was changed every second day and was supplemented with rm GM-CFS to permit 
ESdM to proliferate more rapidly. The microglia-like cells were mechanically isolated at day 28 of 
stage 5 and seeded on PLL-coated culture dishes in N2 medium supplemented with rm GM-CSF to 
obtain a pure ESdM culture (see Fig. 3.1 F).  
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Fig. 3.1: Brightfield pictures during the differentiation of mouse ESCs into microglial precursors.  
(A) ESC colonies (arrow) cultured on irradiated MEF layer. (B) EBs formation in differentiation medium    
(stage 2). (C) EBs after 1 day on a gelatine coated dish. (D) Cells during the stage of nestin
+
 cells selection 
(stage 3). (E) ESdM cells (arrow) appears in-between the other cells. (F) Pure ESdM culture after 
mechanical isolation. Scale bars: 200 µm. 
 
Fig. 3.2: Immunocytochemistry during the differentiation of mouse ESCs into microglial 
precursors.  
(A), (B) Neuronal precursor cells after 2 days of culture in N2 medium supplemented with bFGF and 
laminin. Cells were immunostained against nestin (green). Cells in a mixed neuronal culture 7 days after 
bFGF removal, stained against (C) CD45 (green) for microglia-like cells, (D), (E) β-III-tubulin (green) for 
neurons and (F) GFAP (green) for astrocytes. (G), (H) Microglia-like cells were immunostained with an 
antibody against Iba1 (red). Nuclei were counterstained with DAPI (blue) in all pictures.  
Scale bars: 50 µm. 
 
Results  31 
3.2. Surface marker profile of ESdM 
3.2.1. Flow cytometry 
Flow cytometry analysis of ESdM was performed to assess their surface marker profile and to 
confirm microglial identity. Figure 3.3 shows examples of expression of the eleven different 
markers analyzed.  
ESdM showed high expression levels of microglial markers CD11b, CD11c, CD45, CD49d              
(α4-integrin), CD86 (B7.2) and F4/80 and lower expression of CD29 (β1-integrin), CD68 and I-A/I-E 
(MHC class II). Moreover, it can be observed that stem cells markers like CD34 and CD117 (c-Kit) 
are not expressed by ESdM. 
 
 
 
 
  
  
 
 
 
 
 
 
Fig. 3.3: Representative flow cytometry analysis of ESdM surface markers.  
ESdM expressed high levels of the microglial makers CD11b, CD11c, CD45, CD49d (α4-integrin), CD86 
(B7.2) and F4/80 whereas lower level of CD29 (β1-integrin), CD68 and I-A/I-E (MHC class II). The stem cell 
markers CD117 and CD34 were not expressed by microglia. Curves in blue correspond to unstained cells 
and curves in red correspond to cells that were stained with antibodies. Representative data for three 
individual experiments. 
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3.2.2. Immunocytochemistry 
In addition to flow cytometry, immunocytochemistry of ESdM was used to investigate the 
expression of several microglial markers. All ESdM showed expression of CD11b, CD29                  
(β1-integrin), CD45, CD86 (B7.2) and Iba1. This confirms the microglial identity of ESdM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3. ESdM with inflammatory background have an immunological surface 
marker profile similar to ESdM 
One of the questions being asked was whether it is possible to change the immunological surface 
marker profile of ESdM by treating them just after their differentiation with IFN- (250 U/ml) and 
LPS (250 ng/ml). ESdM obtained after three repetitions of the treatment at two weeks interval 
were called ESdM with inflammatory background. The expression profile of ESdM with 
inflammatory background was compared to that of ESdM using flow cytometry for eleven 
different surface markers. Figure 3.5 shows the expression of CD11b, CD29 (β1-integrin), CD45, 
CD16/CD32, CD86 (B7.2), CD49d (α4-integrin), F4/80, ScavR1, I-A/I-E (MHC class II) and TREM2. As 
it can be seen, the expression of these markers was the same in the case of ESdM and of ESdM 
with inflammatory background. This demonstrates that early treatments with pro-inflammatory 
stimuli did not alter the immunological surface marker profile of ESdM at long term. 
Fig. 3.4: Fluorescent microscopic pictures of ESdM for different microglial markers.  
ESdM were immunostained for different microglial markers (green) and nuclei of cells were counterlabeled 
with DAPI (blue). All ESdM showed expression of CD11b, CD29, CD45, CD86 and Iba1 which confirm their 
microglial identity. Scale bars: 100 μm. 
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Fig. 3.5: Representative flow cytometry analysis of surface markers of ESdM and ESdM with 
inflammatory background.  
ESdM and ESdM with inflammatory background showed the same expression profile of microglial markers 
CD11b, CD29 (β1-integrin), CD45, CD16/CD32, CD86 (B7.2), CD49d (α4-integrin), F4/80, ScavR1, I-A/I-E        
(MHC class II) and TREM2. Orange graphs represent expression of ESdM with inflammatory background and 
green ones show expression of ESdM. Blue and red graphs represent unstained ESdM with inflammatory 
background and unstained ESdM, respectively. Representative data for two individual experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4. Functional analysis of ESdM sub-differentiated into M1 and M2 subtypes 
 
3.4.1. Pro- and anti-inflammatory stimuli induce changes in the morphology of ESdM 
 
Upon activation, the morphology of microglia switches gradually from a ramified to a rounded 
shape (Streit et al., 1999). Moreover, as it can be seen in figure 3.6, the morphology of cells 
treated with 100 U/ml rm IFN-γ + 5 ng/ml LPS do not resemble that of cells treated with rm IL-4 
(40 ng/ml). Indeed, after pro-inflammatory stimulation, lot of cells with a star-like morphology 
were observed in the dishes as well as some rounded cells. However, nearly all cells treated with 
rm IL-4 presented a rounded morphology. The same morphology changes were observed in the 
case of ESdM with inflammatory background. 
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3.4.2. Surface expression of pro- and anti-inflammatory markers on ESdM and ESdM with 
inflammatory background upon pro- and anti-inflammatory stimuli 
Upon activation, microglia express various cell surface markers depending on the type of 
stimulation they underwent. Therefore, flow cytometry and immunocytochemistry were used to 
investigate whether ESdM stimulated either with pro- or anti-inflammatory treatment expressed 
M1 or M2 markers. Five different markers were investigated by flow cytometry, two for M1 
subtype: CD16/32 and CD64 and three for M2 subtype: CD206, ScavR1 and TREM2. By 
immunocytochemistry, CD86, iNOS and CD16/32 makers were studied for M1 subtype and CD206 
and Arg-1 for M2 subtype. Different culture conditions were used to stimulate the cells in order to 
obtain the two different cell populations; M1 and M2 (see Tab. 2.6).  
 
Flow cytometry 
In general, even if the culture conditions were changed, the results obtained by flow cytometry 
were showing similar results (summarized in Fig. 3.7). Indeed, the surface receptor CD16/CD32 
was expressed at the same level by cells treated with M1 stimulation, M2 stimulation and by 
unstimulated (control) cells. Moreover, one can observe a shift of the graphs compared to 
unstained cells, meaning that ESdM expressed CD16/CD32. In the case of CD64, one can observe 
that M1 treatment led to an higher expression of this marker, whereas M2 treatment did not alter 
its expression. CD206 was slightly more expressed by cells treated with rm IL-4 than by cells 
treated with rm IFN-γ and LPS. Moreover, both M1 and M2 treatments induced an increase in the 
Fig. 3.6: Brightfield pictures of ESdM upon pro- or anti-inflammatory stimulation. 
Cells were stimulated either with 100 U/ml rm IFN-γ and 5 ng/ml LPS (B and E) or with 40 ng/ml rm IL-4 (C and F) 
for 48 h. Pictures (A) and (D) show unstimulated ESdM cultured in N2 medium. rm IFN-γ and LPS treatment led 
to a mixed population of ESdM, with round or star-like morphology. However, rm IL-4 treated ESdM mostly 
exhibited a rounded morphology. Scale bars: 100 µm. 
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expression of CD206 compared to unstimulated cells, which showed a slight increase in the 
expression level of CD206 compared to unstained cells. Concerning ScavR1, unexpected results 
were obtained. Indeed, M1 treated cells showed more expression of ScavR1 than M2 treated cells 
in most of the cases. M2 treated cells exhibited the same level of ScavR1 expression as 
unstimulated cells. In general, unstimulated and M2 stimulated cells showed an increase in the 
expression level of ScavR1. TREM2 expression was slightly affected by M1 and M2 treatments. 
Indeed, both treatments led to an increase of TREM2 expression. Moreover, M1 treated cells 
exhibited a slight increase in the expression of TREM2 compared to M2 treated ones. Both 
stimulated and unstimulated cells expressed TREM2 in comparison to unstained cells. 
 
 
 
 
 
 
 
 
Fig. 3.7: Representative flow cytometry analysis of expression of pro- and anti-inflammatory markers 
upon M1 or M2 treatment.  
ESdM were treated either with M1 or M2 treatment (see Tab. 2.6) and used to assess the M1 marker 
expression levels of CD16/CD32 and CD64 and the M2 marker expression levels of CD206, ScavR1 and 
TREM2. The blue graphs represent unstimulated (control) cells, the red correspond to M1 treated cells and 
the green to M2 treated cells. CD16/CD32 expression level was not affected by M1 or M2 treatment. M1 
treatment led to an increase in CD64 expression, whereas M2 treatment did not modified its expression 
level compared to unstimulated cells. CD206 was slightly more expressed by M2 treated cells than by M1 
treated ones. Both treatments led to an increase in CD206 expression level compared to unstimulated cells. 
Moreover, M1 treatment led to an increase of the M2 markers ScavR1 and TREM2. M2 treatment did not 
influence ScavR1 expression level but induced an increase in the expression of TREM2. 
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Immunocytochemistry 
Cells were stimulated with rm IFN-γ (100 U/ml) and LPS (5 ng/ml) for 24 h or 2 successive times 
for 24 h with rm IL-4 (20 ng/ml). Samples were stained with different antibodies (see Tab. 2.2 and 
2.4) and analyzed with fluorescent microscopy using the same parameters for all pictures so that 
the intensity of the fluorescence can be compared between the images. Figure 3.8 demonstrates 
that the intensity of the staining for CD86, CD16/CD32 and iNOS in the case of rm IFN-γ and LPS 
treated cells is higher than that of control or rm IL-4 treated cells. However, it can be observed 
that the two markers assigned to M2, Arg-1 and CD206, were not altered either by M1 or M2 
treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.8: Immunocytochemistry of ESdM for M1 and M2 markers.  
Cells were treated either with IFN-γ (100 U/ml) and LPS (5 ng/ml) for 24 h or with IL-4 (20 ng/ml) every 24 h for 
48 h. Five different markers were investigated using immunocytochemistry. CD86, CD16/32 and iNOS (M1 
markers) were higher expressed upon pro-inflammatory treatment. However, neither M1 nor M2 treatments 
modified the expression of M2 markers (Arg-1 and CD206). Scale bar for all pictures: 100 µm. 
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3.4.3. Pro- and anti-inflammatory stimuli influence the transcription of pro- and anti- 
inflammatory cytokines in ESdM and ESdM with inflammatory background 
One typical feature of microglia is the production of pro- or anti-inflammatory cytokines and of 
reactive oxygen species upon immune stimulation. Therefore, gene transcript levels of the pro-
inflammatory cytokines iNOS, CXCL10 and TNF-α and of the anti-inflammatory molecules IL-10, 
Ym(1/2) and Arg-1 were determined by qRT-PCR after M1 or M2 treatment (see Tab. 2.6) for both 
ESdM and ESdM with inflammatory background. The best results (see Fig. 3.9) were obtained 
after treatment with 100 U/ml IFN-γ + 5 ng/ml LPS for 24 h for M1 stimulation and with 40 ng/ml 
rm IL-4 for 24 h for M2 stimulation. The IL-4 incubation time was shorten compared to previous 
experiments because using qRT-PCR, changes at the RNA level are analyzed, which are detectable 
at earlier time points than changes at the protein level.  
In figure 3.9, it can be observed that M1 treatment significantly increased mRNA transcript levels 
of iNOS (1630-fold ± 51.5, p < 0.00001 in the case of ESdM and 210-fold ± 16.5, p < 0.00001 in the 
case of ESdM with inflammatory background) and CXCL10 (1940-fold ± 328.5, p = 0.001 in the 
case of ESdM and 65-fold ± 6, p < 0.00001 in the case of ESdM with inflammatory background), 
whereas TNF-α mRNA transcript was significantly increased only by 5-fold ± 0.5 (p < 0.00001) in 
ESdM. In the case of ESdM with inflammatory background, TNF-α mRNA transcript was increased 
by 5-fold ± 2, but this increase was not significant. M1 treatment had a small effect on anti-
inflammatory genes in the case of ESdM. Indeed, slight down-regulation of Arg-1 (0.6-fold ± 0.09) 
and IL-10 (0.6-fold ± 0.14) was observed after treatment with rm IFN-γ + LPS. However, Ym(1/2) 
mRNA transcript was not affected by M1 treatment in ESdM. In the case of ESdM with 
inflammatory background, M1 treatment had a stronger effect on anti-inflammatory molecules 
than in the case of ESdM. Actually, Arg-1 mRNA transcript was increased by 29-fold ± 11 and 
Ym(1/2) mRNA transcript by 1.7-fold ± 0.8. However, a down-regulation of IL-10 (0.21-fold ± 0.01) 
transcript level was observed. These changes were not significant. 
After rm IL-4 stimulation, ESdM and ESdM with inflammatory background showed up-regulation 
of anti-inflammatory mRNA transcripts (see Fig. 3.9). Indeed, Arg-1 mRNA transcript was 
significantly up-regulated by 50-fold ± 10 (p = 0.004) in the case of ESdM and not significantly up-
regulated by 610-fold ± 263 in the case of ESdM with inflammatory background. Ym(1/2) mRNA 
transcript showed an up-regulation of 2.5-fold ± 1.3 in the case of ESdM and 9.5-fold ± 4.7 in the 
case of ESdM with inflammatory background and IL-10 of 1.5-fold ± 0.4 in the case of ESdM and   
5-fold ± 1.3 in the case of ESdM with inflammatory background. M2 treatment had only small 
effects on pro-inflammatory genes in both ESdM and ESdM with inflammatory background. 
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CXCL10 was up-regulated by 1.3-fold ± 0.6 in the case of ESdM. However, a down-regulation of 
the mRNA transcripts of iNOS (0.33-fold ± 0.03) and TNF-α (0.29-fold ± 0.1) were observed in the 
case of ESdM upon rm IL-4 treatment. Moreover, upon M2 stimulation, iNOS (0.42-fold ± 0.07), 
CXCL10 (0.49-fold ±0.1) and TNF-α (0.72-fold ± 0.45) were down-regulated in the case of ESdM 
with inflammatory background. 
 
 
 
 
 
Fig. 3.9: Cytokine gene transcripts analysis of ESdM and ESdM with inflammatory background upon pro- 
or anti-inflammatory stimulus. 
(A) ESdM. Pro-inflammatory stimulation (M1) significantly up-regulated iNOS, CXCL10 and TNF-α gene 
transcripts. Anti-inflammatory stimulation (M2) significantly increased Arg-1 gene transcript. Ym(1/2) and IL-10 
were up-regulated by M2 treatment but not significantly. (B) ESdM with inflammatory background. After M1 
treatment, iNOS and CXCL10 gene transcripts were significantly up-regulated. TNF-α gene transcript was also 
increased but not significantly. M2 stimulation led to an up-regulation of the following anti-inflammatory 
molecules gene transcripts: Arg-1, Ym(1/2) and IL-10. 
Data are represented as means ± SEM of three individual experiments and were analyzed using multivariate 
ANOVA. * corresponds to the comparison between stimulated cells and unstimulated (control) cells.  
(** p ≤ 0.01 and *** p ≤ 0.001). 
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The general scheme of cytokine expression after M1 or M2 stimulation was the same in both 
ESdM and ESdM with inflammatory background (see Fig. 3.9). In the case of ESdM with 
inflammatory background, one can observe that the fold increase of iNOS and CXCL10 mRNA 
transcripts after M1 treatment is lower than in ESdM (200-fold versus 1600-fold and 65-fold 
versus 1900-fold, respectively). Moreover, upon M2 stimulation, ESdM with inflammatory 
background expressed higher mRNA levels than ESdM for Arg-1 (600-fold versus 50-fold), Ym(1/2) 
(9.5-fold versus 2.5-fold) and IL-10 (5-fold versus 1.5-fold). One big difference when comparing 
these two cell types appears in the case of Arg-1 upon M1 stimulation. Indeed, ESdM with 
inflammatory background showed an increase in mRNA transcript of 29-fold, whereas ESdM 
showed no increase of this mRNA transcript. 
Taken together, ESdM with inflammatory background have a similar response in gene 
transcription to pro- and anti-inflammatory stimuli compared to ESdM aside for Arg-1. Moreover, 
pro-inflammatory (M1) stimulation led to an increase of genes assigned to M1 subtype and anti-
inflammatory (M2) treatment to an increase of genes from the M2 subtype. 
 
 
3.4.4. Influence of pro- and anti-inflammatory stimulation on the release of pro- and anti-
inflammatory cytokines and cellular signaling molecules by ESdM and ESdM with 
inflammatory background 
Upon stimulation, microglia are able to release cytokines and cellular signaling molecules. These 
features were tested using ELISA and Griess assay. ESdM and ESdM with inflammatory 
background were first stimulated with M1 or M2 treatment (see Tab. 2.6) and thereafter, cell 
culture media was collected and analyzed for concentrations of CXCL10 and IL-10 by ELISA and for 
nitrite by Griess assay.  
CXCL10 was highly expressed and released (7000 pg/ml ± 1000) by cells treated with 100 U/ml    
rm IFN-γ and 5 ng/ml LPS for 24 h (see Fig. 3.10 A). Upon rm IL-4 stimulation (40 ng/ml for 24h), 
cells released only slightly more CXCL10 than unstimulated (control) cells (82.5 pg/ml ± 2.5 versus 
63.5 pg/ml ± 1.5 for ESdM and 70 pg/ml ± 30 versus 49.5 pg/ml ± 7.5 for ESdM with inflammatory 
background). ESdM with inflammatory background showed a lower release of CXCL10 upon M1 
stimulation than ESdM (4050 pg/ml ± 200 versus 7000 pg/ml ± 1000). Even if different pro- and 
anti-inflammatory treatments were tried (see Tab. 2.6), no IL-10 release was detected (data not 
showed). M2 treatment did not led to a detectable release of IL-10, as it would be expected 
according to literature (Mantovani et al., 2004; Martinez et al., 2009). 
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Using Griess assay, it was showed that upon 72 h of stimulation with rm IFN-γ (200 U/ml) and LPS    
(50 ng/ml) ESdM and ESdM with inflammatory background secreted significantly higher levels of 
NO than unstimulated (control) or rm IL-4 treated cells (7.7 µM ± 1.75, p < 0.00001 and                
3.1 µM ± 0.23, p < 0.00001, respectively). However, no nitrite was detected in the medium of 
untreated (control) cells or rm IL-4 (40 ng/ml for 48 h) treated cell. Moreover, the difference 
between the amount of NO released by ESdM compared to the amount released by ESdM with 
inflammatory background was significantly different (p = 0.011). 
Fig. 3.10: CXCL10 and NO release by ESdM or ESdM with inflammatory background upon pro- or anti-
inflammatory stimulus. 
(A) ELISA: Cells were treated with rm IFN-γ (100 U/ml) and LPS (5 ng/ml) or with rm IL-4 (40 ng/ml) for 24 h. ELISA 
kit was used to quantify the concentration of CXCL10 in the medium of untreated (control) and treated cells.         
rm IFN-γ and LPS treatment induced an increase in the release of the pro-inflammatory cytokine CXCL10, which 
was not observed for rm IL-4 treatment. Data are represented as means ± range of two individual experiments.            
(B) Griess: Cells were stimulated with rm IFN-γ (200 U/ml) and LPS (50 ng/ml) for 72 h or with rm IL-4 (40 ng/ml) 
for 48 h. Griess assay was performed to obtain the level of nitrite, which is a breakdown product of NO, in culture 
media of cells. A significant increase in the concentration of nitrite was found in the medium of pro-inflammatory 
treated cells compared to untreated (control) and rm IL-4 treated cells both in the case of ESdM and ESdM with 
inflammatory background. Upon pro-inflammatory treatment, ESdM with inflammatory background showed a 
significant lower level of nitrite in the culture medium compared to the medium of ESdM. Unstimulated cells and 
anti-inflammatory treated cells secreted undetectable levels of NO. Data are represented as means ± SEM of three 
individual experiments and were analyzed using multivariate ANOVA (* p ≤ 0.05 and *** p ≤ 0.001). 
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3.4.5. Phagocytosis ability of ESdM and ESdM with inflammatory background upon pro- 
and anti-inflammatory stimuli 
Phagocytosis capacity is an important feature of activated microglia in the brain. This capacity was 
assayed in vitro using fluorescent labeled microsphere beads. Cells were first treated with M1 and 
M2 treatment (see Tab. 2.6) and then fluorescent labeled microsphere beads were added for     
1.5 h. Flow cytometry analysis was performed to quantify the phagocytosis capacity of ESdM and 
ESdM with inflammatory background. Only cells that phagocytosed more than one bead were 
taken into account as it is not possible to distinguish between internalized beads and beads that 
are attached on the surface of cells by flow cytometry. 
ESdM and ESdM with inflammatory background were able to phagocytose beads and no 
differences in phagocytosis capacity were observed between these two kinds of cells. On average, 
26 % of ESdM or ESdM with inflammatory background phagocytosed more than one bead. 
Moreover, no significant differences were observed in the beads phagocytosis capacity of cells 
upon pro- or anti-inflammatory treatment. Figure 3.11 presents the results obtained by flow 
cytometry upon stimulation with IFN-γ (100 U/ml) and LPS (5 ng/ml) for 24 h or with rm IL-4          
(40 ng/ml) for 48 h.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.11: Phagocytic capacity of ESdM and ESdM with inflammatory background upon pro- and anti-
inflammatory stimulation. 
Cells were treated with rm IFN-γ (100 U/ml) + LPS (5 ng/ml) for 24 h or with rm IL-4 (40 ng/ml) for 48 h. Thereafter, 
fluorescent labeled microsphere beads were added for 1.5 h to the culture medium. Flow cytometry was 
performed to quantify the amount of phagocytic cells. Only cells that phagocytosed more than one bead were 
taken into account. No significant differences were found in the phagocytosis capacity of cells upon pro- or anti-
inflammatory stimuli. 
Data are represented as means ± SEM of three individual experiments and were analyzed using multivariate 
ANOVA.  
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4. DISCUSSION  
The CNS has long been regarded as an immunological privileged environment because of the BBB 
and the lack of lymphatic drainage (Matyszak, 1998). Now, microglia are widely accepted as the 
immune cells of the CNS, monitoring the entire environment and playing a crucial role in the 
detection and removal of foreign molecules that enter the brain (Kreutzberg, 1996; Felter and 
Amigorena, 2005; Nimmerjahn et al., 2005; Graeber and Streit, 2010). The most prominent 
characteristic feature of microglia is their capacity to react to even minor pathological changes in 
the CNS, and to undergo rapid activation in order to challenge harmful stimuli (Kreutzberg, 1996). 
Neuroinflammation has long been considered as having only negative effects on the CNS. 
However, the local immune response is necessary as it allows the clearance of cellular debris, 
secretion of neurotrophic factors and anti-inflammatory cytokines and therefore also has 
beneficial effects on CNS (Minghetti, 2005; Schwartz et al., 2006; Harry and Kraft, 2008). Thus, 
microglia are believed to have both protective and harmful properties, depending on the stimulus 
of activation (Ekdahl et al., 2009; Henkel et al., 2009). On the one hand, microglia adopt a 
cytotoxic phenotype (M1) upon pro-inflammatory stimuli and secrete pro-inflammatory cytokines 
such as IL-1, TNF-α, free radicals like NO and superoxide anions (Goerdt and Orfanos, 1999). These 
molecules are essential for the defense of the brain against intracellular pathogens, bacteria and 
tumors, but their expression also leads to cytotoxic effects and collateral damages to healthy 
tissue (Ding et al., 1988; Martinez et al., 2009). On the other hand, microglia can also be activated 
by a variety of Th2 lymphocyte products such as IL-4 and IL-13, leading to an anti-inflammatory 
phenotype (M2). Microglia secrete high level of anti-inflammatory cytokines and neurotrophic 
factors and therefore mediate immune tolerance and protect the tissues against oxidative 
damage (Goerdt et al., 1999; Ghassabeh et al., 2006). 
In vivo, Th1 cells produce IFN-γ, mediating innate immunity and, Th2 cells secrete IL-4 playing a 
role in acquired immunity. In addition to IL-4, Th2 cells were shown to secrete IL-10 that 
suppresses Th1 cells, and IL-13 which is a cytokine that partially shares ligand binding receptor 
complexes with IL-4 (Mosmann and Coffman, 1989; McKenzie et al., 1993). IFN-γ and IL-4 are two 
opposite cytokines that possess cross-regulatory properties and coordinate the two 
fundamentally opposite immune responses of microglia subtypes M1 and M2. 
It is known that macrophages can be polarized in vitro into a cytotoxic (M1) phenotype using 
microbial product like LPS and pro-inflammatory cytokines such as IFN-γ (Mantovani et al., 2004). 
Macrophages can also be sub-differentiated by anti-inflammatory cytokines such as IL-4 into a 
protective phenotype (M2). Although sub-differentiation of macrophages into M1 subtype is 
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widely described in literature, the M2 phenotype remains poorly characterized (Goerdt et al., 
1999; Nair et al., 2003; Mantovani et al., 2004; Ghassabeh et al., 2006; Mosser and Edwards, 
2008; Leidi et al., 2009; Kigerl et al., 2009). Moreover, little is known about the polarization 
capacity of microglial cells (Butovsky et al., 2005; Butovsky et al., 2006; Michelucci et al., 2009) 
and it is therefore still unclear if the same observations reported in macrophages can be 
transferred to microglia.  
The work at hand focused on the investigation of in vitro microglial polarization into the two 
extremes of the activation spectrum, the pro-inflammatory subtype M1; and the anti-
inflammatory subtype M2. Indeed, it would be of great interest to generate stable lines of 
polarized microglial cells in high numbers and to use them as a natural cell-based vehicle for gene 
therapy of neurological disorders. M2 polarized immune cells have been shown to have beneficial 
effects in the CNS, for example on inflammation, by producing anti-inflammatory cytokines and 
neurotrophic factors (Goerdt et al., 1999) and on the clearance function of oligomeric Aβ by 
expressing scavenger receptor CD36 and the Aβ-degrading enzymes neprilysin and insulin-
degrading enzyme (Shimizu et al., 2008). Moreover, cells polarized into M2 subtype have been 
shown to induce oligodendrogenesis and neurogenesis, a process partly mediated by microglial 
release of insulin-like growth factor-I, a key factor in neurogenesis and oligodendrogenesis 
(Butovsky et al., 2006). M1 polarized cells release high level of NO which has been shown to be 
tumoricidal whereas M2 is associated with angiogenesis, which is a key event in tumor growth 
and progession (Sinha et al., 2005; Martinez et al., 2008; Weigert and Brune, 2008). 
In this study, the molecules used to induce M1 or M2 subtype were rm IFN-γ + LPS or rm IL-4, 
respectively. Indeed, it is known that in the presence of IFN-γ and LPS, microglia and tissue 
macrophages will most likely adopt M1 phenotype whereas in the presence of IL-4 they will rather 
adopt M2 phenotype (Mantovani et al., 2004; Michelucci et al., 2009). Different culture 
conditions were tested in order to obtain these two different cell subtypes. Investigation of the 
phenotype of the stimulated cells was done using flow cytometry, immunocytochemistry,         
qRT-PCR, ELISA, Griess and phagocytosis assay. Primary microglia can be obtained by isolation and 
enrichment from mixed glial cultures derived from early mouse brain tissue or by isolation of 
microglia directly by flow cytometry (Ford et al., 1995; Havenith et al., 1998). However, these 
procedures are time consuming and the cell yield is low. Therefore, many researchers have used 
oncogenically transformed microglial cell lines like BV-2 or N9 instead of primary microglia (Blasi 
et al., 1990; Bocchini et al., 1992) but these cells may not be suitable as replacement for primary 
microglia because of the oncogenic transformations. Napoli and colleagues recently developed a 
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protocol for differentiation of unlimited number of microglial precursors from ESCs which were 
shown to be an adequate substitute for primary microglia as they display properties alike of 
primary microglia (Napoli et al., 2009; Beutner et al., 2010). Indeed, ESdM were shown to have 
similar surface marker profile and similar response to IFN-γ and LPS stimulation as primary 
microglia. Moreover, using RNA microarray it was shown that ESdM display a comparable gene 
expression profile as primary microglia for 19 000 over 20 000 genes (data obtained by Clara 
Beutner, unpublished). In mouse, ESdM engraft into postnatal brain tissue after in vitro 
transplantation and show microglial phenotype and morphology (Napoli et al., 2009; Beutner et 
al., 2010).   
4.1. Phenotype of ESdM 
During the differentiation protocol of ESCs into microglial precursors, immunocytochemistry 
revealed cells positive for the neuronal precursor marker nestin already in the third to the last 
stage of the protocol. Moreover, cells positive for the microglial markers Iba1 and CD45, the 
astrocytic marker GFAP as well as the neuronal marker β-III-tubulin were found to coexist in the 
differentiation dishes at stage 5 (see Fig. 3.2). The microglial like cells were manually isolated from 
the differentiation dishes 45 days after the initiation of EBs formation, and were expanded in 
order to obtain a pure population of ESdM. Before using ESdM for experiments, their phenotype 
in regard to surface marker expression was determined.  
The differentiation based on surface marker expression between microglia and macrophages that 
have entered the CNS is a big problem since microglia share most markers with macrophages 
(Guillemin and Brew, 2004). Therefore it is necessary to use a combination of three or four 
markers together to distinguish without ambiguity microglia from macrophages (Guillemin and 
Brew, 2004). In literature, microglia are described to have the following surface marker profile: 
CD68+, CD45low, CD11b+, CD11chigh, MHC class II+, Iba1+ and F4/80+ (Guillemin and Brew, 2004). In 
order to confirm the microglial identity of ESdM obtained with the differentiation protocol, flow 
cytometry was performed for different microglial markers as well as for two stem cell markers. 
Results showed that ESdM highly expressed the microglial markers CD11b, CD11c, CD45, CD49d 
(α4-integrin), CD86 (B7.2) and F4/80 (see Fig. 3.3). CD11b also known as integrin alpha M is one 
protein subunit that forms the macrophage-1 antigen (Mac-1). It is expressed by granulocytes, 
macrophages, myeloid-derived dendritic cells, natural killer cells and microglia and has been 
implicated in diverse cells responses, including phagocytosis, cell mediated killing, chemotaxis, 
and cellular activation (Solovjov et al., 2005). CD11c is also called the integrin αx and is a type I 
transmembrane protein expressed on the monocyte/macrophage lineage. CD45 is a member of 
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the protein tyrosine phosphatase family that is an essential regulator of B- and T-cell antigen 
receptor signaling (Townsend et al., 2004). CD49d, also known as integrin α4 chain, is expressed 
on most peripheral lymphocytes, thymocytes, and monocytes/macrophages. Integrin expression 
is a necessity for microglia, since they have to be able of antigen presentation, adhesion and 
immune responses. CD86, also named B7.2, is expressed on antigen-presenting cells and provides 
costimulatory signals necessary for the activation and survival of T cells. F4/80 is a cell surface 
glycoprotein exclusively expressed on microglia/macrophage (Austyn and Gordon, 1981; Perry et 
al., 1985). The role of this glycoprotein has long been unknown but a report from Lin and 
colleagues provides direct evidence for a role of the F4/80 molecule in adaptive immunity (Lin et 
al., 2005). Moreover, ESdM expressed CD29 (β1-integrin), CD68 and I-A/I-E (MHC class II), but to a 
lower extend than the previously described markers (see Fig. 3.3). CD29 is an integrin unit 
associated with very late antigen receptors. Microglial cells are known to successfully present 
antigens in several CNS diseases, a process that depends on MHC class I and II molecules 
(Gebicke-Haerter, 2001). However, it is known that resting microglia do not express high levels of 
MHC class II (Kreutzberg, 1996; Steit et al., 1999), which is in accordance with our findings. 
Because ESdM were generated from mouse ESCs, the expression of the stem cell markers CD34 
and CD117 (c-kit) were analyzed to confirm their commitment to differentiation. ESdM did not 
express these two markers, indicating that indeed they were committed to differentiation (see 
Fig. 3.3). The surface marker expression profile found for ESdM in this work fits with data already 
obtained by Neumann’s group and is similar to the expression profile of primary microglia (Napoli 
et al., 2009). In addition, the microglial identity of ESdM was confirmed by immunocytochemistry 
with antibodies directed against CD11b, CD29, CD45, and CD86 (see Fig. 3.4). Iba1 is a 
macrophage/microglia-specific calcium-binding protein and is probably the most versatile 
immunocytochemistry marker for microglial cells. Calcium ions exert their signaling activity 
through association with various calcium binding proteins, many of which are classified into the 
EF hand protein family. Iba1 is a member of this family and functions as an adapter molecule that 
mediates calcium signals in the monocytic lineage, including microglia (Ito et al., 1998). ESdM 
were all positive for this microglial marker. In summary, ESdM are committed to differentiation 
and express the same surface marker profile as primary microglia. 
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4.2. Sub-differentiation of ESdM and ESdM with inflammatory background 
into M1 and M2 subtypes 
In order to polarize ESdM into the cytotoxic subtype M1 or into the neuroprotective subtype M2, 
different culture conditions were used. The molecules used to push ESdM to M1 or M2 
phenotype were rm IFN-γ + LPS or rm IL-4, respectively. It is known that macrophages express 
different surface markers depending on the stimulation (Goerdt and Orfanos, 1999; Mantovani et 
al., 2004; Martinez et al., 2009). Therefore, flow cytometry and immunocytochemistry were first 
used to investigate ESdM surface expression profile of different markers assigned to M1 or M2 
subtype. Immunocytochemical analysis revealed that after rm IFN-γ + LPS stimulation, the M1 
markers CD16/CD32, CD86 and iNOS were more expressed by ESdM than after rm IL-4 treatment 
which is in accordance with knowledge about macrophages (see Fig. 3.8; Goerdt and Orfanos, 
1999; Mantovani et al., 2004). However, neither M1 nor M2 treatment altered the expression of 
the M2 markers Arg-1 and CD206 which should be higher expressed by cells stimulated with anti-
inflammatory cytokines like IL-4 and IL-13 (Mantovani et al., 2004; Martinez et al., 2009). 
Surprisingly, it was not possible to confirm all these results by flow cytometry (see Fig. 3.7). 
Indeed, using flow cytometry, no alteration of the M1 marker CD16/CD32 was found after M1 or 
M2 stimulation. However, an increase in the expression of the M1 marker CD64 after pro-
inflammatory stimulation was observed. The expression of three markers assigned to the M2 
subtype; CD206, ScavR1 and TREM2 was also investigated. For CD206, a slight increase in the 
expression following rm IL-4 treatment was observed which is also found in macrophages 
(Mantovani et al., 2004; Martinez et al., 2009). It is known that CD206, also known as macrophage 
mannose receptor 1, expression is inhibited by IFN-γ but is enhanced upon IL-4 stimulation (Stein 
et al., 1992). Unexpected results were obtained for ScavR1 and TREM2, since rm IFN-γ + LPS 
treatment increased their expression. According to literature concerning macrophages, these two 
markers should be higher expressed upon M2 stimulation (Mantovani et al., 2004; Ghassabeh et 
al., 2009). Results obtained by flow cytometry have shown that up-regulation of markers assigned 
to M1 or M2 subtype were not stimuli-specific. Moreover, ESdM expressed M2 markers even in 
the case of unstimulated cells, but this was not the case for M1 markers. Therefore, the 
hypothesis that the ESdM might already be pushed toward M2 subtype was formulated. To 
counteract this, ESdM were treated directly after their appearance in the differentiation dishes 
with 250 U/ml rm IFN-γ and 250 ng/ml LPS for three times at two weeks interval. These early 
treated cells were called ESdM with inflammatory background and were cultured like normal 
ESdM. These treatments should aim to shift the phenotype of ESdM toward M1. Using flow 
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cytometry to compare the maker profile of ESdM with inflammatory background and of normal 
ESdM (see Fig. 3.5), it was found that both cell types expressed same level of the microglial 
markers CD11b, CD29 (β1-integrin), CD45, CD49d (α4-integrin), I-A/I-E (MHC class II) and F4/80. 
Moreover, same expression levels of the M1 markers CD16/CD32, CD86 and of the M2 markers 
ScavR1 and TREM2 were found in both ESdM types. These results indicate that either early 
treatments with rm IFN-γ and LPS did not polarize the cells into M1 subtype or that the 
phenotype of ESdM induced by pro-inflammatory treatment is not stable over time and is 
reversible (Schwartz et al., 2006). 
Having both ESdM and ESdM with inflammatory background, it was interesting to investigate 
whether these two cell types respond differently because of the early treatments to pro- or anti-
inflammatory stimuli. Therefore, a variety of assays was used to analyze the phenotype of ESdM 
and ESdM with inflammatory background upon treatment with different amounts of rm IFN-γ and 
LPS or rm IL-4 for various times. 
One typical feature of microglia is the inducibility of pro- and anti-inflammatory cytokines and 
reactive oxygen species upon immune stimulation (Streit, 2000; Hanisch, 2002; Mantovani et al., 
2004; Ladeby et al., 2005). For this reason, qRT-PCR was used to determine gene transcript levels 
of the pro-inflammatory cytokines iNOS, CXCL10 and TNF-α and of the anti-inflammatory 
molecules Ym(1/2), IL-10 and Arg-1 upon M1 or M2 stimulation. iNOS is the inducible form of NO 
synthase, which catalyze the production of NO from L-arginine. Excessive levels of NO were 
shown to promote tissue injury and to contribute to a variety of diseases (Clancy et al., 1998). 
CXCL10 is also called IFN-γ-inducible protein 10 and is a chemoattractant for activated T cells into 
sites of tissue inflammation (Dufour et al., 2002). TNF-α modulates CD14 expression and acts in an 
autocrine and paracrine manner to activate the population of immune cells across the brain 
parenchyma (Nadeau and Rivest, 2000). Ym is a protein of the chitinase family, and is largely 
distributed in mammalian bodies. Chitinases are glycoproteins that generally comprise a 
substrate-binding module as well as a catalytic domain (Nio et al., 2004). However, Ym1 and Ym2 
lack this chitinase activity but are able to detect specific carbohydrates on cell surfaces or in 
extracellular matrix and they function as endogenous lectins to affect cell growth, differentiation 
and migration (Nio et al., 2004). IL-10 is an anti-inflammatory cytokine that down-regulates the 
expression of Th1 cytokines, MHC class II and costimulatory molecules. Expression of Arg-1 
induces a shift of arginine metabolism form the IFN-γ induced production of NO via iNOS toward 
production of ornithine and polyamines, which are important for example for wound healing 
(Hesse et al., 2001). ESdM and ESdM with inflammatory background showed specific responses to  
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M1 and M2 treatments, which is in agreement with previous findings in macrophages (see Fig. 
3.9; Mantovani et al., 2004; Ghassabeh et al., 2009). Indeed, rm IFN-γ + LPS treatment led to an 
up-regulation of all three pro-inflammatory molecules whereas rm IL-4 treatment led to an 
increase of the anti-inflammatory molecules. An interesting outcome was that ESdM with 
inflammatory background showed a lower up-regulation of iNOS (200-fold versus 1600-fold) and 
CXCL10 (65-fold versus 1900-fold) upon pro-inflammatory stimulation than ESdM. However, ESdM 
with inflammatory background displayed stronger response than ESdM for all three M2 genes 
upon pro- or anti-inflammatory stimulation.  
Knowing that there was a difference in the gene expression level of pro- and anti-inflammatory 
cytokines upon M1 or M2 stimulation, it was interesting to know if these stimulations also 
influence the release of inflammatory mediators and reactive oxygen species by the cells. 
Therefore, ELISA kits to measure the amount of CXCL10 and of IL-10 released in the culture media 
of cells stimulated either with M1 or M2 treatment were used. Moreover, a Griess assay was used 
to quantify the nitrite concentration in the cell culture media. Nitrite is a nonvolatile and stable 
breakdown product of NO and therefore its concentration correlates with the amount of NO 
released by cells. Using these tools, it was shown that upon 24 h of rm IFN-γ and LPS stimulation, 
cells released more CXCL10 in the medium than in the case of rm IL-4 treated cells or control cells 
(see Fig. 3.10 A) which is expected for M1 polarized cells. Moreover, ESdM with inflammatory 
background did not release as much as CXCL10 upon M1 stimulation as ESdM (4050 pg/ml versus 
7000 pg/ml, respectively). IL-10 cytokine was undetectable in all the stimulation conditions 
tested. Even after anti-inflammatory treatment, no IL-10 could be detected in the medium of 
cells. This result is surprising since an up-regulation of IL-10 gene transcript after rm IL-4 
stimulation was observed with qRT-PCR. Therefore, it seems that either the IL-10 level secreted by 
cells was too low to be detected or that the conditions used to trigger the M2 phenotype were 
not optimal. Moreover, pro-inflammatory treatment led to a significant increase of nitrite 
concentration in the culture medium, which is a hint for M1 polarization. However, no nitrite was 
found in the medium of rm IL-4 treated cells as well as in the medium of untreated cells. Again, 
ESdM showed a stronger response to pro-inflammatory treatment as ESdM with inflammatory 
background by secreting significantly more NO than ESdM with inflammatory background.  
In summary, results obtained from immunocytochemistry, qRT-PCR, ELISA kit and Griess assay 
indicated that ESdM and ESdM with inflammatory background can be polarized into the cytotoxic 
subtype M1 using rm IFN-γ and LPS. After first flow cytometry experiments, it was hypothesized 
that ESdM were pushed toward M2. However, after further analysis this hypothesis seems 
improbable since untreated ESdM never showed properties assigned to M2 subtype. Moreover, 
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even if a significant increase in the gene transcript of Arg-1 upon rm IL-4 stimulation in the case of 
ESdM was observed, no other results validated the fact that ESdM can be sub-differentiated into 
the neuroprotective subtype M2 using rm IL-4. This could be due to the fact that the stimulations 
used to polarize the cells were not optimal. However, one should keep in mind that ESdM are 
generated completely in vitro and therefore never received any stimulus from the CNS 
environment. Consequently, ESdM might not respond like primary microglia to pro- and anti-
inflammatory stimuli. Moreover, all the experiments were done in vitro and therefore do not 
mimic the 3D environment of the brain properly. One can hypothesize that other signals than IL-4 
are necessary to trigger M2 phenotype. Indeed, it is known that microglia communicate with 
other cortical cells (Nimmerjahn et al., 2005; Wake et al., 2009). Some signals for example from 
dying neurons might be needed in addition to IL-4 in order to trigger an effective M2 response. 
Moreover, it is known that M2 phenotype mediate down-regulation of inflammation (Goerdt et 
al., 1999), and therefore microglial cells might need signals from an inflammatory environment to 
be able to trigger an effective M2 response. Another point is that mice from C57BL/6 strain are 
known to be Th1 responder, meaning that for example their immune cells are more easily 
activated to produce NO by IFN-γ or LPS than cells from Th2 strains (Mills et al., 2000). This could 
be an explanation why it is more difficult to obtain the M2 subtype compared to the M1 subtype 
using ESdM derived from C57BL/6 strain. It would therefore be interesting to use ESCs form 
another strain known to be Th2 responder, for example BALB/c, for the differentiation protocol 
and see whether ESdM obtain from Th2 strains respond differently to pro- and anti-inflammatory 
stimulation. 
An interesting observation was that ESdM with inflammatory background did not respond like 
ESdM to pro- and anti-inflammatory treatments. Indeed, it was observed in all the experiments 
performed that ESdM with inflammatory background were not as sensitive to pro-inflammatory 
treatment and that their responses were lower compared to ESdM. This could be explained by the 
“negative priming” effect (Schwartz et al., 2006) as ESdM with inflammatory background were 
already exposed three times to rm IFN-γ and LPS. This would suggest that ESdM have a kind of 
memory of the stimuli they underwent and that the response of ESdM cells is influenced not only 
by the type of stimulation they received but also by their history (Schwartz et al., 2006). 
Microglia cells possess different phagocytic receptors, which allow them to transform into potent 
phagocytic cells upon activation (Kreutzberg, 1996; Raivich et al., 1999; Napoli and Neumann, 
2009). In this work, in vitro phagocytosis capacity of ESdM and ESdM with inflammatory 
background was assessed using labeled microsphere beads. Flow cytometry was used to quantify 
the number of cells that phagocytosed more than one bead. Only cells that showed signal 
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intensity from more than one bead were taken into account as it is not possible to distinguish 
between internalized beads and beads that are attached on the surface of cells. Results showed 
that ESdM and ESdM with inflammatory background are able to phagocytose beads (see Fig. 
3.11). However, no difference in the percentage of cells that phagocytosed more than one bead 
was observed between unstimulated, pro- or anti-inflammatory stimulated cells. This is not in 
accordance with data obtained by Beutner and colleagues as they have shown that upon LPS 
activation there is an increase in the ESdM phagocytic capacity (Beutner et al., 2010). However, 
they used much higher LPS concentrations than used in this study (500 ng/ml versus 5 ng/ml or 
250 ng/ml) and did not combine it with rm IFN-γ. The results obtained here could be explained by 
the fact that beads phagocytosis is an unspecific event as beads are inert material and therefore is 
not influenced by pro- or anti-inflammatory cytokines. It is known that microglial phagocytosis is 
mainly regulated by signals received by microglia from their environment (Napoli and Neumann, 
2009). Moreover, specific receptors are required to induce phagocytosis by microglial cells (Napoli 
and Neumann, 2009). For example, toll like receptors recognize microbes and allow their removal 
and simultaneously trigger a pro-inflammatory reaction (Ravichandran, 2003). Microglia also 
recognize phosphatidylserine residues expressed on the membrane of apoptotic cells. 
Phagocytosis of apoptotic cells induces an anti-inflammatory response (Ravichandran, 2003; 
Napoli and Neumann, 2009). Therefore, it would be interesting to use dying cells for testing the 
phagocytosis capacity of ESdM upon pro- and anti-inflammatory stimulation as they secrete 
factors that could be important for specific phagocytosis by polarized ESdM. 
In conclusion, similar results as for macrophages were obtained for the M1 subtype. Indeed, 
ESdM treated with rm IFN-γ + LPS showed up-regulation of pro-inflammatory cytokines and 
secreted large amount of the chemokines CXCL10 and NO which render them cytotoxic. However, 
no optimal stimulation protocol to push the ESdM into M2 subtype could be developed. It seems 
that other signals than IL-4 are necessary to trigger a neuroprotective phenotype. Additional 
experiments have to be performed in order to better understand the mechanisms of microglial 
sub-differentiation and to find out about the stability of the M1 or M2 phenotype acquired by 
ESdM after pro- or anti-inflammatory stimulation. 
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